Changes in b4d034f: update

				ABCA3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ABCA3.md]]

          +[[include:tables/table1_ABCA3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ABCB1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ABCB1.md]]

          +[[include:tables/table1_ABCB1.md]]

           [[include:tables/mermaid_ABCB1.md]]

				ABCC9.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ABCC9]]

          +[[include:tables/table1_ABCC9]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ABI3BP.md
			
          @@ -15,7 +15,7 @@ Mutations were first described in DLBCL in 2013 by Morin et al.[@morinMutational

           ## Relevance tier by entity

          -[[include:table1_ABI3BP]]

          +[[include:tables/table1_ABI3BP]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ABL2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ABL2.md]]

          +[[include:tables/table1_ABL2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ACAD9.md
			
          @@ -13,7 +13,7 @@ Due to [minimal support](ACAD9#representative-mutation) in the original primary 

           ## Relevance tier by entity

          -[[include:table1_ACAD9]]

          +[[include:tables/table1_ACAD9]]

           ## Warnings

				ACE.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](ACE#representative-mutation) in the original primary da

           ## Relevance tier by entity

          -[[include:table1_ACE]]

          +[[include:tables/table1_ACE]]

           ## Warnings

				ACSM3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ACSM3]]

          +[[include:tables/table1_ACSM3]]

           [[include:tables/mermaid_ACSM3.md]]

				ACSS2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ACSS2]]

          +[[include:tables/table1_ACSS2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ACSS3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ACSS3.md]]

          +[[include:tables/table1_ACSS3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ACTB.md
			
          @@ -16,7 +16,7 @@ ACTB is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) 

           ## Relevance tier by entity

          -[[include:table1_ACTB]]

          +[[include:tables/table1_ACTB]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ACTG1.md
			
          @@ -19,7 +19,7 @@ The function of mutations in ACTB and ACTG1 have not yet been determined.[@witje

           ## Relevance tier by entity

          -[[include:table1_ACTG1]]

          +[[include:tables/table1_ACTG1]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ACTN1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ACTN1]]

          +[[include:tables/table1_ACTN1]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADAM2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADAM2]]

          +[[include:tables/table1_ADAM2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADAMTS1.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_ADAMTS1]]

          +[[include:tables/table1_ADAMTS1]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADAMTS15.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADAMTS15]]

          +[[include:tables/table1_ADAMTS15]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADAMTS5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADAMTS5]]

          +[[include:tables/table1_ADAMTS5]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADAMTSL3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADAMTSL3]]

          +[[include:tables/table1_ADAMTSL3]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADD2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADD2]]

          +[[include:tables/table1_ADD2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADH7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADH7]]

          +[[include:tables/table1_ADH7]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ADNP.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ADNP]]

          +[[include:tables/table1_ADNP]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AFAP1L2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AFAP1L2]]

          +[[include:tables/table1_AFAP1L2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AGA.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AGA]]

          +[[include:tables/table1_AGA]]

				AGO4.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AGO4]]

          +[[include:tables/table1_AGO4]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AHR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AHR]]

          +[[include:tables/table1_AHR]]

           [[include:tables/mermaid_AHR.md]]

				AICDA.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AICDA]]

          +[[include:tables/table1_AICDA]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AKAP6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AKAP6]]

          +[[include:tables/table1_AKAP6]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AKAP8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AKAP8]]

          +[[include:tables/table1_AKAP8]]

				AKAP9.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AKAP9]]

          +[[include:tables/table1_AKAP9]]

           [[include:tables/mermaid_AKAP9.md]]

				ALAS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ALAS1]]

          +[[include:tables/table1_ALAS1]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ALDH1L2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ALDH1L2]]

          +[[include:tables/table1_ALDH1L2]]

           [[include:tables/mermaid_ALDH1L2.md]]

				ALDH3A2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ALDH3A2]]

          +[[include:tables/table1_ALDH3A2]]

           [[include:tables/mermaid_ALDH3A2.md]]

				ALPK2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ALPK2]]

          +[[include:tables/table1_ALPK2]]

           ## Warnings

				AMAC1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AMAC1.md]]

          +[[include:tables/table1_AMAC1.md]]

				AMIGO3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AMIGO3.md]]

          +[[include:tables/table1_AMIGO3.md]]

				AMN.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AMN.md]]

          +[[include:tables/table1_AMN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AMOTL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AMOTL1.md]]

          +[[include:tables/table1_AMOTL1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AMPH.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AMPH.md]]

          +[[include:tables/table1_AMPH.md]]

				ANK2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ANK2.md]]

          +[[include:tables/table1_ANK2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ANKLE2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ANKLE2.md]]

          +[[include:tables/table1_ANKLE2.md]]

				ANKRD12.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_ANKRD12.md]]

          +[[include:tables/table1_ANKRD12.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ANKRD17.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ANKRD17.md]]

          +[[include:tables/table1_ANKRD17.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ANKRD44.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ANKRD44.md]]

          +[[include:tables/table1_ANKRD44.md]]

				ANTXR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ANTXR1.md]]

          +[[include:tables/table1_ANTXR1.md]]

				AOC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AOC2.md]]

          +[[include:tables/table1_AOC2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AP1G2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AP1G2.md]]

          +[[include:tables/table1_AP1G2.md]]

				APBB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_APBB1.md]]

          +[[include:tables/table1_APBB1.md]]

				APC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_APC.md]]

          +[[include:tables/table1_APC.md]]

				APMAP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_APMAP.md]]

          +[[include:tables/table1_APMAP.md]]

				APOA5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_APOA5.md]]

          +[[include:tables/table1_APOA5.md]]

				APP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_APP.md]]

          +[[include:tables/table1_APP.md]]

				ARAP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARAP2.md]]

          +[[include:tables/table1_ARAP2.md]]

				ARHGAP20.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARHGAP20.md]]

          +[[include:tables/table1_ARHGAP20.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARHGEF1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARHGEF1.md]]

          +[[include:tables/table1_ARHGEF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARHGEF15.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARHGEF15.md]]

          +[[include:tables/table1_ARHGEF15.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARHGEF17.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARHGEF17.md]]

          +[[include:tables/table1_ARHGEF17.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ARID1A.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene have been experimentally demonstrated to ca

           ## Relevance tier by entity

          -[[include:table1_ARID1A]]

          +[[include:tables/table1_ARID1A]]

           ## Mutation incidence in large cohorts

				ARID1B.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARID1B.md]]

          +[[include:tables/table1_ARID1B.md]]

           ## Warnings

				ARID5B.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARID5B.md]]

          +[[include:tables/table1_ARID5B.md]]

           ## Warnings

				ARIH2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ARIH2.md]]

          +[[include:tables/table1_ARIH2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ASXL3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ASXL3.md]]

          +[[include:tables/table1_ASXL3.md]]

				ATIC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATIC.md]]

          +[[include:tables/table1_ATIC.md]]

				ATM.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_ATM.md]]

          +[[include:tables/table1_ATM.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP10A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATP10A.md]]

          +[[include:tables/table1_ATP10A.md]]

				ATP11C.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATP11C.md]]

          +[[include:tables/table1_ATP11C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP1A2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATP1A2.md]]

          +[[include:tables/table1_ATP1A2.md]]

				ATP2A3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATP2A3.md]]

          +[[include:tables/table1_ATP2A3.md]]

				ATP2C2.md
			
          @@ -16,7 +16,7 @@ Due to [minimal support](ATP2C2#representative-mutation) in the original primary

           ## Relevance tier by entity

          -[[include:table1_ATP2C2.md]]

          +[[include:tables/table1_ATP2C2.md]]

           ## Warnings

				ATP6AP1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATP6AP1.md]]

          +[[include:tables/table1_ATP6AP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP6V0A1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ATP6V0A1.md]]

          +[[include:tables/table1_ATP6V0A1.md]]

				ATP6V1A.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_ATP6V1A.md]]

          +[[include:tables/table1_ATP6V1A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATP6V1B2.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_ATP6V1B2.md]]

          +[[include:tables/table1_ATP6V1B2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ATR.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_ATR.md]]

          +[[include:tables/table1_ATR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				AXDND1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_AXDND1.md]]

          +[[include:tables/table1_AXDND1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				B2M.md
			
          @@ -20,7 +20,7 @@ B2M mutations in B-cell lymphomas, particularly in DLBCL and PMBCL, lead to redu

           ## Relevance tier by entity

          -[[include:table1_B2M.md]]

          +[[include:tables/table1_B2M.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				B4GALNT2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_B4GALNT2.md]]

          +[[include:tables/table1_B4GALNT2.md]]

				BACH2.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in BL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_BACH2]]

          +[[include:tables/table1_BACH2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BAI1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BAI1.md]]

          +[[include:tables/table1_BAI1.md]]

				BAZ1A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BAZ1A.md]]

          +[[include:tables/table1_BAZ1A.md]]

				BCAT2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BCAT2.md]]

          +[[include:tables/table1_BCAT2.md]]

				BCL10.md
			
          @@ -22,7 +22,7 @@ BCL10 missense mutations in the CARD domain and truncating mutations have distin

           ## Relevance tier by entity

          -[[include:table1_BCL10.md]]

          +[[include:tables/table1_BCL10.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCL11A.md
			
          @@ -12,7 +12,7 @@ BCL11A (B-cell lymphoma/leukemia 11A) is a transcription factor involved in the 

           ## Relevance tier by entity

          -[[include:table1_BCL11A.md]]

          +[[include:tables/table1_BCL11A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCL2.md
			
          @@ -17,7 +17,7 @@ Although missense mutations may not be under positive selective pressure in the 

           ## Relevance tier by entity

          -[[include:table1_BCL2.md]]

          +[[include:tables/table1_BCL2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCL2L10.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BCL2L10.md]]

          +[[include:tables/table1_BCL2L10.md]]

				BCL6.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in BL/FL/DLBCL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_BCL6]]

          +[[include:tables/table1_BCL6]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCL7A.md
			
          @@ -21,7 +21,7 @@ Driver mutations affecting this gene in BL/DLBCL/FL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_BCL7A]]

          +[[include:tables/table1_BCL7A]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCOR.md
			
          @@ -16,7 +16,7 @@ BCOR acts as a co-repressor of BCL6, and mutations in BCOR could impair its bind

           ## Relevance tier by entity

          -[[include:table1_BCOR.md]]

          +[[include:tables/table1_BCOR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BCR.md
			
          @@ -15,7 +15,7 @@ BCR (Breakpoint Cluster Region Protein) is one of [a number of genes](https://gi

           ## Relevance tier by entity

          -[[include:table1_BCR.md]]

          +[[include:tables/table1_BCR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BIRC3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BIRC3.md]]

          +[[include:tables/table1_BIRC3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BIRC6.md
			
          @@ -15,7 +15,7 @@ BIRC6, as a negative regulator of non-canonical NF-κB signaling, is implicated 

           ## Relevance tier by entity

          -[[include:table1_BIRC6.md]]

          +[[include:tables/table1_BIRC6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BLM.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BLM.md]]

          +[[include:tables/table1_BLM.md]]

				BMP7.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BMP7]]

          +[[include:tables/table1_BMP7]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BMPR1A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BMPR1A.md]]

          +[[include:tables/table1_BMPR1A.md]]

				BRAF.md
			
          @@ -21,7 +21,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_BRAF.md]]

          +[[include:tables/table1_BRAF.md]]

           ## Warnings

				BRCA1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BRCA1.md]]

          +[[include:tables/table1_BRCA1.md]]

				BRCA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BRCA2.md]]

          +[[include:tables/table1_BRCA2.md]]

				BRD4.md
			
          @@ -14,7 +14,7 @@ Due to [minimal support](BRD4#representative-mutation) in the original primary d

           ## Relevance tier by entity

          -[[include:table1_BRD4.md]]

          +[[include:tables/table1_BRD4.md]]

           ## Warnings

				BRINP3.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_BRINP3.md]]

          +[[include:tables/table1_BRINP3.md]]

           ## Warnings

				BRSK1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BRSK1.md]]

          +[[include:tables/table1_BRSK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BSCL2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BSCL2.md]]

          +[[include:tables/table1_BSCL2.md]]

				BTAF1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_BTAF1.md]]

          +[[include:tables/table1_BTAF1.md]]

				BTBD3.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_BTBD3.md]]

          +[[include:tables/table1_BTBD3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BTG1.md
			
          @@ -21,7 +21,7 @@ Another study demonstrated that specific BTG1 mutations afford germinal center (

           ## Relevance tier by entity

          -[[include:table1_BTG1.md]]

          +[[include:tables/table1_BTG1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				BTG2.md
			
          @@ -16,7 +16,7 @@ BTG2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) 

           ## Relevance tier by entity

          -[[include:table1_BTG2.md]]

          +[[include:tables/table1_BTG2.md]]

           ## Warnings

				BTK.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_BTK.md]]

          +[[include:tables/table1_BTK.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				C12orf35.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_C12orf35.md]]

          +[[include:tables/table1_C12orf35.md]]

				C16orf48.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_C16orf48.md]]

          +[[include:tables/table1_C16orf48.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				C6orf103.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_C6orf103.md]]

          +[[include:tables/table1_C6orf103.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				C6orf27.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](C6orf27#representative-mutation) in the original primar

           ## Relevance tier by entity

          -[[include:table1_C6orf27.md]]

          +[[include:tables/table1_C6orf27.md]]

           ## Warnings

				C9.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_C9.md]]

          +[[include:tables/table1_C9.md]]

				CAD.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](CAD#representative-mutation) in the original primary da

           ## Relevance tier by entity

          -[[include:table1_CAD.md]]

          +[[include:tables/table1_CAD.md]]

           ## Warnings

				CADPS2.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_CADPS2.md]]

          +[[include:tables/table1_CADPS2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CAMTA1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CAMTA1.md]]

          +[[include:tables/table1_CAMTA1.md]]

				CAPN5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CAPN5.md]]

          +[[include:tables/table1_CAPN5.md]]

				CAPN7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CAPN7.md]]

          +[[include:tables/table1_CAPN7.md]]

				CARD11.md
			
          @@ -20,7 +20,7 @@ The functional effect of CARD11 mutations in DLBCL was explored in the original 

           ## Relevance tier by entity

          -[[include:table1_CARD11.md]]

          +[[include:tables/table1_CARD11.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CARD4.md
			
          @@ -14,7 +14,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CARD4.md]]

          +[[include:tables/table1_CARD4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CASP8.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_CASP8.md]]

          +[[include:tables/table1_CASP8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CBFA2T3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CBFA2T3.md]]

          +[[include:tables/table1_CBFA2T3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CBLB.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_CBLB.md]]

          +[[include:tables/table1_CBLB.md]]

           ## Warnings

				CBX3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CBX3.md]]

          +[[include:tables/table1_CBX3.md]]

				CCDC132.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CCDC132.md]]

          +[[include:tables/table1_CCDC132.md]]

				CCDC46.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CCDC46.md]]

          +[[include:tables/table1_CCDC46.md]]

				CCDC97.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CCDC97.md]]

          +[[include:tables/table1_CCDC97.md]]

				CCL4.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CCL4.md]]

          +[[include:tables/table1_CCL4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CCND1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CCND1.md]]

          +[[include:tables/table1_CCND1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CCND3.md
			
          @@ -17,7 +17,7 @@ Somatic mutations in CCND3 often stabilize the Cyclin D3 protein by altering the

           ## Relevance tier by entity

          -[[include:table1_CCND3]]

          +[[include:tables/table1_CCND3]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CCNF.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CCNF.md]]

          +[[include:tables/table1_CCNF.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CCT6B.md
			
          @@ -16,7 +16,7 @@ Due to [minimal support](CCT6B#representative-mutations) in the original primary

           ## Relevance tier by entity

          -[[include:table1_CCT6B.md]]

          +[[include:tables/table1_CCT6B.md]]

           ## Warnings

				CD22.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_CD22.md]]

          +[[include:tables/table1_CD22.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD274.md
			
          @@ -14,7 +14,7 @@ Although rare, mutations have the potential to impact PD-L1 expression and could

           ## Relevance tier by entity

          -[[include:table1_CD274.md]]

          +[[include:tables/table1_CD274.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD36.md
			
          @@ -14,7 +14,7 @@ CD36 is a transmembrane glycoprotein involved in fatty acid metabolism, glucose 

           ## Relevance tier by entity

          -[[include:table1_CD36.md]]

          +[[include:tables/table1_CD36.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD44.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CD44.md]]

          +[[include:tables/table1_CD44.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD58.md
			
          @@ -19,7 +19,7 @@ This is often accompanied by mutations in the β2-Microglobulin gene, which furt

           ## Relevance tier by entity

          -[[include:table1_CD58.md]]

          +[[include:tables/table1_CD58.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD70.md
			
          @@ -22,7 +22,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_CD70.md]]

          +[[include:tables/table1_CD70.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD74.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CD74.md]]

          +[[include:tables/table1_CD74.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD79A.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CD79A.md]]

          +[[include:tables/table1_CD79A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD79B.md
			
          @@ -24,7 +24,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_CD79B.md]]

          +[[include:tables/table1_CD79B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD83.md
			
          @@ -19,7 +19,7 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al[@mor

           ## Relevance tier by entity

          -[[include:table1_CD83.md]]

          +[[include:tables/table1_CD83.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CD9B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CD9B.md]]

          +[[include:tables/table1_CD9B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDC123.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDC123.md]]

          +[[include:tables/table1_CDC123.md]]

				CDC27.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDC27.md]]

          +[[include:tables/table1_CDC27.md]]

				CDC42BPB.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[

           ## Relevance tier by entity

          -[[include:table1_CDC42BPB.md]]

          +[[include:tables/table1_CDC42BPB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDC73.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in BL in 2012 by Love et al[@loveGen

           ## Relevance tier by entity

          -[[include:table1_CDC73.md]]

          +[[include:tables/table1_CDC73.md]]

           ## Warnings

				CDH1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH1.md]]

          +[[include:tables/table1_CDH1.md]]

				CDH10.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH10.md]]

          +[[include:tables/table1_CDH10.md]]

				CDH17.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](CDH17#representative-mutations) in the original primary

           ## Relevance tier by entity

          -[[include:table1_CDH17.md]]

          +[[include:tables/table1_CDH17.md]]

           ## Warnings

				CDH2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH2.md]]

          +[[include:tables/table1_CDH2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDH5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH5.md]]

          +[[include:tables/table1_CDH5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDH7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH7.md]]

          +[[include:tables/table1_CDH7.md]]

				CDH8.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH8.md]]

          +[[include:tables/table1_CDH8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDH9.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDH9.md]]

          +[[include:tables/table1_CDH9.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDK3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDK3.md]]

          +[[include:tables/table1_CDK3.md]]

				CDKN1A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDKN1A.md]]

          +[[include:tables/table1_CDKN1A.md]]

				CDKN2A.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_CDKN2A.md]]

          +[[include:tables/table1_CDKN2A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CDKN2C.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CDKN2C.md]]

          +[[include:tables/table1_CDKN2C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CECR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CECR1.md]]

          +[[include:tables/table1_CECR1.md]]

				CELSR2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CELSR2.md]]

          +[[include:tables/table1_CELSR2.md]]

				CEP164.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CEP164.md]]

          +[[include:tables/table1_CEP164.md]]

				CGN.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CGN.md]]

          +[[include:tables/table1_CGN.md]]

				CHD1.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_CHD1.md]]

          +[[include:tables/table1_CHD1.md]]

           ## Warnings

				CHD3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CHD3.md]]

          +[[include:tables/table1_CHD3.md]]

				CHD4.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CHD4.md]]

          +[[include:tables/table1_CHD4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CHD8.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CHD8]]

          +[[include:tables/table1_CHD8]]

           ## Warnings

				CHEK2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CHEK2.md]]

          +[[include:tables/table1_CHEK2.md]]

				CHMP4C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CHMP4C.md]]

          +[[include:tables/table1_CHMP4C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CHRM5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CHRM5.md]]

          +[[include:tables/table1_CHRM5.md]]

				CHST2.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_CHST2.md]]

          +[[include:tables/table1_CHST2.md]]

           ## Warnings

				CIC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CIC.md]]

          +[[include:tables/table1_CIC.md]]

				CIITA.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_CIITA.md]]

          +[[include:tables/table1_CIITA.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CILP.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CILP.md]]

          +[[include:tables/table1_CILP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CISH.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CISH.md]]

          +[[include:tables/table1_CISH.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CLGN.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CLGN.md]]

          +[[include:tables/table1_CLGN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CNBP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CNBP.md]]

          +[[include:tables/table1_CNBP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CNGA4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CNGA4.md]]

          +[[include:tables/table1_CNGA4.md]]

				CNKSR2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CNKSR2.md]]

          +[[include:tables/table1_CNKSR2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CNOT2.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_CNOT2.md]]

          +[[include:tables/table1_CNOT2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CNOT6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CNOT6.md]]

          +[[include:tables/table1_CNOT6.md]]

				CNP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CNP.md]]

          +[[include:tables/table1_CNP.md]]

				CNTN6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CNTN6.md]]

          +[[include:tables/table1_CNTN6.md]]

				CNTNAP5.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al.[@mo

           ## Relevance tier by entity

          -[[include:table1_CNTNAP5.md]]

          +[[include:tables/table1_CNTNAP5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				COL11A1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_COL11A1.md]]

          +[[include:tables/table1_COL11A1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				COL12A1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_COL12A1.md]]

          +[[include:tables/table1_COL12A1.md]]

				COL16A1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_COL16A1.md]]

          +[[include:tables/table1_COL16A1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				COL4A2.md
			
          @@ -17,7 +17,7 @@ Due to [minimal support](COL4A2#representative-mutations) in the original primar

           ## Relevance tier by entity

          -[[include:table1_COL4A2.md]]

          +[[include:tables/table1_COL4A2.md]]

           ## Warnings

				COL5A2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_COL5A2.md]]

          +[[include:tables/table1_COL5A2.md]]

				COQ7.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_COQ7.md]]

          +[[include:tables/table1_COQ7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CORO2A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CORO2A.md]]

          +[[include:tables/table1_CORO2A.md]]

				CORO7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CORO7.md]]

          +[[include:tables/table1_CORO7.md]]

				CPNE8.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[

           ## Relevance tier by entity

          -[[include:table1_CPNE8.md]]

          +[[include:tables/table1_CPNE8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CPS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CPS1.md]]

          +[[include:tables/table1_CPS1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CPXM2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CPXM2.md]]

          +[[include:tables/table1_CPXM2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CREBBP.md
			
          @@ -21,7 +21,7 @@ Mutations in CREBBP and EP300 affect a common pathway and have been described as

           ## Relevance tier by entity

          -[[include:table1_CREBBP.md]]

          +[[include:tables/table1_CREBBP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CRELD2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CRELD2.md]]

          +[[include:tables/table1_CRELD2.md]]

				CRIP1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CRIP1.md]]

          +[[include:tables/table1_CRIP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CRTC3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CRTC3.md]]

          +[[include:tables/table1_CRTC3.md]]

				CRYBG3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CRYBG3.md]]

          +[[include:tables/table1_CRYBG3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CSF2RB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CSF2RB.md]]

          +[[include:tables/table1_CSF2RB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CSNK1A1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CSNK1A1.md]]

          +[[include:tables/table1_CSNK1A1.md]]

				CSNK2A1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CSNK2A1.md]]

          +[[include:tables/table1_CSNK2A1.md]]

				CST7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CST7.md]]

          +[[include:tables/table1_CST7.md]]

				CTCF.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CTCF.md]]

          +[[include:tables/table1_CTCF.md]]

           ## Warnings

				CTNNA2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CTNNA2.md]]

          +[[include:tables/table1_CTNNA2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CTNNA3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CTNNA3.md]]

          +[[include:tables/table1_CTNNA3.md]]

				CTSS.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in FL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_CTSS.md]]

          +[[include:tables/table1_CTSS.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CXCR4.md
			
          @@ -21,7 +21,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_CXCR4.md]]

          +[[include:tables/table1_CXCR4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CXCR5.md
			
          @@ -14,7 +14,7 @@ CXCR5 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)

           ## Relevance tier by entity

          -[[include:table1_CXCR5.md]]

          +[[include:tables/table1_CXCR5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CYB5D1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CYB5D1.md]]

          +[[include:tables/table1_CYB5D1.md]]

           ## Warnings

				CYP24A1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CYP24A1.md]]

          +[[include:tables/table1_CYP24A1.md]]

				CYP2A6.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CYP2A6.md]]

          +[[include:tables/table1_CYP2A6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				CYP2C18.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CYP2C18.md]]

          +[[include:tables/table1_CYP2C18.md]]

				CYP4F22.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](CYP4F22#representative-mutation) in the original primar

           ## Relevance tier by entity

          -[[include:table1_CYP4F22.md]]

          +[[include:tables/table1_CYP4F22.md]]

           ## Warnings

				CYTSB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CYTSB.md]]

          +[[include:tables/table1_CYTSB.md]]

				CYYR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_CYYR1.md]]

          +[[include:tables/table1_CYYR1.md]]

				DAZAP1.md
			
          @@ -13,7 +13,7 @@ This gene has some recurrent sites of mutations (hot spots). The mutation patter

           ## Relevance tier by entity

          -[[include:table1_DAZAP1.md]]

          +[[include:tables/table1_DAZAP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DCAF6.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2017 by Reddy et al.[@re

           ## Relevance tier by entity

          -[[include:table1_DCAF6.md]]

          +[[include:tables/table1_DCAF6.md]]

           ## Warnings

				DCHS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DCHS1.md]]

          +[[include:tables/table1_DCHS1.md]]

				DCP1B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DCP1B.md]]

          +[[include:tables/table1_DCP1B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DDB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DDB1.md]]

          +[[include:tables/table1_DDB1.md]]

				DDX10.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DDX10.md]]

          +[[include:tables/table1_DDX10.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DDX3X.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in DLBCL/BL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_DDX3X]]

          +[[include:tables/table1_DDX3X]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DGCR8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DGCR8.md]]

          +[[include:tables/table1_DGCR8.md]]

				DGKB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DGKB.md]]

          +[[include:tables/table1_DGKB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DHCR7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DHCR7.md]]

          +[[include:tables/table1_DHCR7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DHDH.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DHDH.md]]

          +[[include:tables/table1_DHDH.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DHX15.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[

           ## Relevance tier by entity

          -[[include:table1_DHX15.md]]

          +[[include:tables/table1_DHX15.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DHX16.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_DHX16.md]]

          +[[include:tables/table1_DHX16.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DHX33.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DHX33.md]]

          +[[include:tables/table1_DHX33.md]]

				DIAPH2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DIAPH2.md]]

          +[[include:tables/table1_DIAPH2.md]]

				DIAPH3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DIAPH3.md]]

          +[[include:tables/table1_DIAPH3.md]]

				DICER1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DICER1.md]]

          +[[include:tables/table1_DICER1.md]]

           <<Warn("The variants reported in this gene in DLBCL failed QC")>>

				DIP2B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DIP2B.md]]

          +[[include:tables/table1_DIP2B.md]]

				DLC1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DLC1.md]]

          +[[include:tables/table1_DLC1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DLGAP1.md
			
          @@ -14,7 +14,7 @@ Due to [minimal support](DLGAP1#representative-mutation) in the original primary

           ## Relevance tier by entity

          -[[include:table1_DLGAP1.md]]

          +[[include:tables/table1_DLGAP1.md]]

           ## Warnings

				DLGAP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DLGAP2.md]]

          +[[include:tables/table1_DLGAP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DMD.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DMD.md]]

          +[[include:tables/table1_DMD.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DMXL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DMXL1.md]]

          +[[include:tables/table1_DMXL1.md]]

				DNAH12.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNAH12.md]]

          +[[include:tables/table1_DNAH12.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DNAH5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNAH5.md]]

          +[[include:tables/table1_DNAH5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DNAH7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNAH7.md]]

          +[[include:tables/table1_DNAH7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DNAI1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNAI1.md]]

          +[[include:tables/table1_DNAI1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DNAJC6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNAJC6.md]]

          +[[include:tables/table1_DNAJC6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DNM2.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_DNM2.md]]

          +[[include:tables/table1_DNM2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DNMT1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNMT1.md]]

          +[[include:tables/table1_DNMT1.md]]

           ## Warnings

				DNMT3A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNMT3A.md]]

          +[[include:tables/table1_DNMT3A.md]]

           ## Warnings

				DNMT3B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DNMT3B.md]]

          +[[include:tables/table1_DNMT3B.md]]

				DOCK1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DOCK1.md]]

          +[[include:tables/table1_DOCK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DOCK2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DOCK2.md]]

          +[[include:tables/table1_DOCK2.md]]

				DOCK5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DOCK5.md]]

          +[[include:tables/table1_DOCK5.md]]

				DOCK6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DOCK6.md]]

          +[[include:tables/table1_DOCK6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DOLK.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DOLK.md]]

          +[[include:tables/table1_DOLK.md]]

				DPYD.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DPYD.md]]

          +[[include:tables/table1_DPYD.md]]

				DSC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSC2.md]]

          +[[include:tables/table1_DSC2.md]]

				DSC3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSC3.md]]

          +[[include:tables/table1_DSC3.md]]

				DSCAML1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSCAML1.md]]

          +[[include:tables/table1_DSCAML1.md]]

				DSEL.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSEL.md]]

          +[[include:tables/table1_DSEL.md]]

				DSG2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSG2.md]]

          +[[include:tables/table1_DSG2.md]]

				DSG4.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSG4.md]]

          +[[include:tables/table1_DSG4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DSP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DSP.md]]

          +[[include:tables/table1_DSP.md]]

				DTNB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DTNB.md]]

          +[[include:tables/table1_DTNB.md]]

				DTX1.md
			
          @@ -14,7 +14,7 @@ Mutations in the DTX1 gene, which encodes the E3 ubiquitin ligase Deltex 1, have

           ## Relevance tier by entity

          -[[include:table1_DTX1.md]]

          +[[include:tables/table1_DTX1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DTX3L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DTX3L.md]]

          +[[include:tables/table1_DTX3L.md]]

				DUOXA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DUOXA2.md]]

          +[[include:tables/table1_DUOXA2.md]]

				DUPD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DUPD1.md]]

          +[[include:tables/table1_DUPD1.md]]

				DUSP2.md
			
          @@ -19,7 +19,7 @@ The mutation pattern in DLBCL implies the preferential accumulation of *inactiva

           ## Relevance tier by entity

          -[[include:table1_DUSP2.md]]

          +[[include:tables/table1_DUSP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				DUSP27.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DUSP27.md]]

          +[[include:tables/table1_DUSP27.md]]

				DUSP9.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DUSP9.md]]

          +[[include:tables/table1_DUSP9.md]]

				DYNC1H1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DYNC1H1.md]]

          +[[include:tables/table1_DYNC1H1.md]]

				DYNC1I1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_DYNC1I1.md]]

          +[[include:tables/table1_DYNC1I1.md]]

				E2F2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_E2F2.md]]

          +[[include:tables/table1_E2F2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EBF1.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL/FL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_EBF1.md]]

          +[[include:tables/table1_EBF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ECGF1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ECGF1.md]]

          +[[include:tables/table1_ECGF1.md]]

				ECT2L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ECT2L.md]]

          +[[include:tables/table1_ECT2L.md]]

				EDNRB.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EDNRB.md]]

          +[[include:tables/table1_EDNRB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EEF1A1.md
			
          @@ -14,7 +14,7 @@ This gene has some recurrent sites of mutations (hot spots). The mutation patter

           ## Relevance tier by entity

          -[[include:table1_EEF1A1.md]]

          +[[include:tables/table1_EEF1A1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EGFR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EGFR.md]]

          +[[include:tables/table1_EGFR.md]]

				EGR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EGR1.md]]

          +[[include:tables/table1_EGR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EGR2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EGR2.md]]

          +[[include:tables/table1_EGR2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EHD1.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EHD1.md]]

          +[[include:tables/table1_EHD1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EIF2AK3.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EIF2AK3.md]]

          +[[include:tables/table1_EIF2AK3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EIF2AK4.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EIF2AK4.md]]

          +[[include:tables/table1_EIF2AK4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EIF2C4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EIF2C4.md]]

          +[[include:tables/table1_EIF2C4.md]]

           ## Warnings

				EIF4A1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EIF4A1.md]]

          +[[include:tables/table1_EIF4A1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ELP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ELP2.md]]

          +[[include:tables/table1_ELP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EML2.md
			
          @@ -17,7 +17,7 @@ Due to [minimal support](EML2#representative-mutation) in the original primary d

           ## Relevance tier by entity

          -[[include:table1_EML2.md]]

          +[[include:tables/table1_EML2.md]]

           ## Warnings

				ENTPD3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ENTPD3.md]]

          +[[include:tables/table1_ENTPD3.md]]

           ## Warnings

				EP300.md
			
          @@ -18,7 +18,7 @@ Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal i

           ## Relevance tier by entity

          -[[include:table1_EP300.md]]

          +[[include:tables/table1_EP300.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EPHA3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EPHA3.md]]

          +[[include:tables/table1_EPHA3.md]]

				EPHA5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EPHA5.md]]

          +[[include:tables/table1_EPHA5.md]]

				EPHA7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EPHA7.md]]

          +[[include:tables/table1_EPHA7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EPHB2.md
			
          @@ -14,7 +14,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EPHB2]]

          +[[include:tables/table1_EPHB2]]

           ## Warnings

				EPPK1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EPPK1.md]]

          +[[include:tables/table1_EPPK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ERAP1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ERAP1.md]]

          +[[include:tables/table1_ERAP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ERAP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ERAP2.md]]

          +[[include:tables/table1_ERAP2.md]]

				ERBB3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ERBB3.md]]

          +[[include:tables/table1_ERBB3.md]]

				ERN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ERN2.md]]

          +[[include:tables/table1_ERN2.md]]

				ESX1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ESX1.md]]

          +[[include:tables/table1_ESX1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ETNPPL.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ETNPPL.md]]

          +[[include:tables/table1_ETNPPL.md]]

				ETS1.md
			
          @@ -18,7 +18,7 @@ The mutation pattern in DLBCL implies the preferential accumulation of *inactiva

           ## Relevance tier by entity

          -[[include:table1_ETS1.md]]

          +[[include:tables/table1_ETS1.md]]

           ## Warnings

				ETV6.md
			
          @@ -22,7 +22,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_ETV6.md]]

          +[[include:tables/table1_ETV6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EWSR1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EWSR1.md]]

          +[[include:tables/table1_EWSR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EXOSC6.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EXOSC6.md]]

          +[[include:tables/table1_EXOSC6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EXTL3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EXTL3.md]]

          +[[include:tables/table1_EXTL3.md]]

				EZH1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EZH1.md]]

          +[[include:tables/table1_EZH1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EZH2.md
			
          @@ -23,7 +23,7 @@ Combination therapies including EZH2 inhibitors are also under exploration for D

           ## Relevance tier by entity

          -[[include:table1_EZH2]]

          +[[include:tables/table1_EZH2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				EZR.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_EZR.md]]

          +[[include:tables/table1_EZR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FAIM.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAIM.md]]

          +[[include:tables/table1_FAIM.md]]

				FAM129B.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAM129B.md]]

          +[[include:tables/table1_FAM129B.md]]

           ## Warnings

				FAM161A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAM161A.md]]

          +[[include:tables/table1_FAM161A.md]]

				FAM38B.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAM38B.md]]

          +[[include:tables/table1_FAM38B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FAM62C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAM62C.md]]

          +[[include:tables/table1_FAM62C.md]]

				FANCD2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FANCD2.md]]

          +[[include:tables/table1_FANCD2.md]]

				FAS.md
			
          @@ -21,7 +21,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_FAS.md]]

          +[[include:tables/table1_FAS.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FAT1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAT1.md]]

          +[[include:tables/table1_FAT1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FAT2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAT2.md]]

          +[[include:tables/table1_FAT2.md]]

				FAT4.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FAT4.md]]

          +[[include:tables/table1_FAT4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FBLN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FBLN2.md]]

          +[[include:tables/table1_FBLN2.md]]

				FBXO11.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL/BL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_FBXO11]]

          +[[include:tables/table1_FBXO11]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FBXO31.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FBXO31.md]]

          +[[include:tables/table1_FBXO31.md]]

				FBXW7.md
			
          @@ -20,7 +20,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_FBXW7.md]]

          +[[include:tables/table1_FBXW7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FGD3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FGD3.md]]

          +[[include:tables/table1_FGD3.md]]

				FGFR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FGFR1.md]]

          +[[include:tables/table1_FGFR1.md]]

				FGFR3.md
			
          @@ -16,7 +16,7 @@ Due to [minimal support](FGFR3#representative-mutation) in the original primary 

           ## Relevance tier by entity

          -[[include:table1_FGFR3.md]]

          +[[include:tables/table1_FGFR3.md]]

           ## Warnings

				FGFRL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FGFRL1.md]]

          +[[include:tables/table1_FGFRL1.md]]

				FIGN.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FIGN.md]]

          +[[include:tables/table1_FIGN.md]]

				FLNA.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FLNA.md]]

          +[[include:tables/table1_FLNA.md]]

				FLNC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FLNC.md]]

          +[[include:tables/table1_FLNC.md]]

				FLT1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FLT1.md]]

          +[[include:tables/table1_FLT1.md]]

				FLYWCH1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FLYWCH1.md]]

          +[[include:tables/table1_FLYWCH1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FMO2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FMO2.md]]

          +[[include:tables/table1_FMO2.md]]

				FN1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FN1.md]]

          +[[include:tables/table1_FN1.md]]

				FNDC1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FNDC1.md]]

          +[[include:tables/table1_FNDC1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FOXC1.md
			
          @@ -12,7 +12,7 @@ FOXC1 is a transcription factor that regulates genes involved in cell growth, di

           ## Relevance tier by entity

          -[[include:table1_FOXC1.md]]

          +[[include:tables/table1_FOXC1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FOXO1.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in FL/DLBCL/BL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_FOXO1.md]]

          +[[include:tables/table1_FOXO1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FOXP1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FOXP1.md]]

          +[[include:tables/table1_FOXP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FRMPD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FRMPD1.md]]

          +[[include:tables/table1_FRMPD1.md]]

				FTCD.md
			
          @@ -19,7 +19,7 @@ Due to [minimal support](FTCD#representative-mutation) in the original primary d

           ## Relevance tier by entity

          -[[include:table1_FTCD.md]]

          +[[include:tables/table1_FTCD.md]]

           ## Warnings

				FUBP1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FUBP1.md]]

          +[[include:tables/table1_FUBP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FUT5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FUT5.md]]

          +[[include:tables/table1_FUT5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				FZD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FZD1.md]]

          +[[include:tables/table1_FZD1.md]]

				FZD3.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_FZD3.md]]

          +[[include:tables/table1_FZD3.md]]

           ## Warnings

				FZR1.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_FZR1.md]]

          +[[include:tables/table1_FZR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GABRA1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GABRA1.md]]

          +[[include:tables/table1_GABRA1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GABRA2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GABRA2.md]]

          +[[include:tables/table1_GABRA2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GABRG1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GABRG1.md]]

          +[[include:tables/table1_GABRG1.md]]

				GAK.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_GAK.md]]

          +[[include:tables/table1_GAK.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GATA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GATA2.md]]

          +[[include:tables/table1_GATA2.md]]

				GATA3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GATA3.md]]

          +[[include:tables/table1_GATA3.md]]

				GBP7.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GBP7.md]]

          +[[include:tables/table1_GBP7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GCN1L1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GCN1L1.md]]

          +[[include:tables/table1_GCN1L1.md]]

				GCSAM.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GCSAM.md]]

          +[[include:tables/table1_GCSAM.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GGTLA4.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GGTLA4.md]]

          +[[include:tables/table1_GGTLA4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GJA8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GJA8.md]]

          +[[include:tables/table1_GJA8.md]]

				GJB4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GJB4.md]]

          +[[include:tables/table1_GJB4.md]]

				GNA13.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in BL/FL/DLBCL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_GNA13]]

          +[[include:tables/table1_GNA13]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GNAI2.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_GNAI2]]

          +[[include:tables/table1_GNAI2]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GNAS.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GNAS.md]]

          +[[include:tables/table1_GNAS.md]]

           ## Warnings

				GOLGA5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GOLGA5.md]]

          +[[include:tables/table1_GOLGA5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GOPC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GOPC.md]]

          +[[include:tables/table1_GOPC.md]]

				GPC5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPC5.md]]

          +[[include:tables/table1_GPC5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GPD2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPD2.md]]

          +[[include:tables/table1_GPD2.md]]

				GPR126.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPR126.md]]

          +[[include:tables/table1_GPR126.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GPR133.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPR133.md]]

          +[[include:tables/table1_GPR133.md]]

				GPR15.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPR15.md]]

          +[[include:tables/table1_GPR15.md]]

				GPR98.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPR98.md]]

          +[[include:tables/table1_GPR98.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GPS2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GPS2.md]]

          +[[include:tables/table1_GPS2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GRB2.md
			
          @@ -16,7 +16,7 @@ Further research is needed to elucidate its specific role in DLBCL.

           ## Relevance tier by entity

          -[[include:table1_GRB2.md]]

          +[[include:tables/table1_GRB2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GREM2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GREM2.md]]

          +[[include:tables/table1_GREM2.md]]

				GRHPR.md
			
          @@ -13,7 +13,7 @@ GRHPR is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)

           ## Relevance tier by entity

          -[[include:table1_GRHPR.md]]

          +[[include:tables/table1_GRHPR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GRIA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GRIA2.md]]

          +[[include:tables/table1_GRIA2.md]]

				GRIK5.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GRIK5.md]]

          +[[include:tables/table1_GRIK5.md]]

           ## Warnings

				GRIN2A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GRIN2A.md]]

          +[[include:tables/table1_GRIN2A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GRM5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GRM5.md]]

          +[[include:tables/table1_GRM5.md]]

				GRM6.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GRM6.md]]

          +[[include:tables/table1_GRM6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GSG2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GSG2.md]]

          +[[include:tables/table1_GSG2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				GTSE1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_GTSE1.md]]

          +[[include:tables/table1_GTSE1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				H1-4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_H1-4.md]]

          +[[include:tables/table1_H1-4.md]]

				H1-5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_H1-5.md]]

          +[[include:tables/table1_H1-5.md]]

				H1FOO.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_H1FOO.md]]

          +[[include:tables/table1_H1FOO.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				H6PD.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_H6PD.md]]

          +[[include:tables/table1_H6PD.md]]

				HACE1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HACE1.md]]

          +[[include:tables/table1_HACE1.md]]

				HCK.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HCK.md]]

          +[[include:tables/table1_HCK.md]]

				HDAC7.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HDAC7.md]]

          +[[include:tables/table1_HDAC7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HECW2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HECW2.md]]

          +[[include:tables/table1_HECW2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HELLS.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HELLS.md]]

          +[[include:tables/table1_HELLS.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HEPH.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HEPH.md]]

          +[[include:tables/table1_HEPH.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HERC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HERC2.md]]

          +[[include:tables/table1_HERC2.md]]

				HFE.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HFE.md]]

          +[[include:tables/table1_HFE.md]]

				HIPK3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIPK3.md]]

          +[[include:tables/table1_HIPK3.md]]

				HIST1H1B.md
			
          @@ -13,7 +13,7 @@ This is one of several genes that encode linker histone proteins that are recurr

           ## Relevance tier by entity

          -[[include:table1_HIST1H1B.md]]

          +[[include:tables/table1_HIST1H1B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H1C.md
			
          @@ -15,7 +15,7 @@ Mutations are often found in the globular domain of the protein, which is critic

           ## Relevance tier by entity

          -[[include:table1_HIST1H1C.md]]

          +[[include:tables/table1_HIST1H1C.md]]

           ## Warnings

				HIST1H1D.md
			
          @@ -14,7 +14,7 @@ Mutations are often found in the globular domain of the protein, which is critic

           ## Relevance tier by entity

          -[[include:table1_HIST1H1D.md]]

          +[[include:tables/table1_HIST1H1D.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H1E.md
			
          @@ -16,7 +16,7 @@ Mutations in this gene were first described in DLBCL in 2013 by Morin et al.[@mo

           ## Relevance tier by entity

          -[[include:table1_HIST1H1E]]

          +[[include:tables/table1_HIST1H1E]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2AC.md
			
          @@ -14,7 +14,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom

           ## Relevance tier by entity

          -[[include:table1_HIST1H2AC.md]]

          +[[include:tables/table1_HIST1H2AC.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2AD.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2AD.md]]

          +[[include:tables/table1_HIST1H2AD.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2AG.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2AG.md]]

          +[[include:tables/table1_HIST1H2AG.md]]

           ## Warnings

				HIST1H2AL.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2AL.md]]

          +[[include:tables/table1_HIST1H2AL.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2AM.md
			
          @@ -14,7 +14,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom

           ## Relevance tier by entity

          -[[include:table1_HIST1H2AM.md]]

          +[[include:tables/table1_HIST1H2AM.md]]

           ## Warnings

				HIST1H2BC.md
			
          @@ -13,7 +13,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom

           ## Relevance tier by entity

          -[[include:table1_HIST1H2BC.md]]

          +[[include:tables/table1_HIST1H2BC.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2BD.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2BD.md]]

          +[[include:tables/table1_HIST1H2BD.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2BG.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2BG.md]]

          +[[include:tables/table1_HIST1H2BG.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2BK.md
			
          @@ -16,7 +16,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom

           ## Relevance tier by entity

          -[[include:table1_HIST1H2BK.md]]

          +[[include:tables/table1_HIST1H2BK.md]]

           ## Warnings

				HIST1H2BM.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2BM.md]]

          +[[include:tables/table1_HIST1H2BM.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H2BO.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H2BO.md]]

          +[[include:tables/table1_HIST1H2BO.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H3A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3A.md]]

          +[[include:tables/table1_HIST1H3A.md]]

				HIST1H3B.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3B.md]]

          +[[include:tables/table1_HIST1H3B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H3D.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3D.md]]

          +[[include:tables/table1_HIST1H3D.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H3G.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3G.md]]

          +[[include:tables/table1_HIST1H3G.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H3H.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3H.md]]

          +[[include:tables/table1_HIST1H3H.md]]

           ## Warnings

				HIST1H3I.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3I.md]]

          +[[include:tables/table1_HIST1H3I.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H3J.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H3J.md]]

          +[[include:tables/table1_HIST1H3J.md]]

           ## Warnings

				HIST1H4E.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H4E.md]]

          +[[include:tables/table1_HIST1H4E.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST1H4I.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H4I.md]]

          +[[include:tables/table1_HIST1H4I.md]]

				HIST1H4J.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST1H4J.md]]

          +[[include:tables/table1_HIST1H4J.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST2H2BE.md
			
          @@ -13,7 +13,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom

           ## Relevance tier by entity

          -[[include:table1_HIST2H2BE.md]]

          +[[include:tables/table1_HIST2H2BE.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HIST4H4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HIST4H4.md]]

          +[[include:tables/table1_HIST4H4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HK3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HK3.md]]

          +[[include:tables/table1_HK3.md]]

				HLA-A.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_HLA-A.md]]

          +[[include:tables/table1_HLA-A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-B.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_HLA-B.md]]

          +[[include:tables/table1_HLA-B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-C.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_HLA-C.md]]

          +[[include:tables/table1_HLA-C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-DMA.md
			
          @@ -12,7 +12,7 @@ Mutations in this gene are relatively rare in DLBCL overall.

           ## Relevance tier by entity

          -[[include:table1_HLA-DMA.md]]

          +[[include:tables/table1_HLA-DMA.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-DMB.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL by [Hübschmann et al](pape

           ## Relevance tier by entity

          -[[include:table1_HLA-DMB.md]]

          +[[include:tables/table1_HLA-DMB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-DQA1.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_HLA-DQA1.md]]

          +[[include:tables/table1_HLA-DQA1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-DQB1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HLA-DQB1.md]]

          +[[include:tables/table1_HLA-DQB1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HLA-DRB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HLA-DRB1.md]]

          +[[include:tables/table1_HLA-DRB1.md]]

				HMGB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HMGB1.md]]

          +[[include:tables/table1_HMGB1.md]]

				HNF1B.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HNF1B.md]]

          +[[include:tables/table1_HNF1B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HNRNPD.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HNRNPD.md]]

          +[[include:tables/table1_HNRNPD.md]]

				HNRNPH1.md
			
          @@ -16,7 +16,7 @@ The common HNRNPH1 mutations cause deregulated splicing and increased expression

           ## Relevance tier by entity

          -[[include:table1_HNRNPH1.md]]

          +[[include:tables/table1_HNRNPH1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HNRNPR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HNRNPR.md]]

          +[[include:tables/table1_HNRNPR.md]]

				HNRNPU.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HNRNPU]]

          +[[include:tables/table1_HNRNPU]]

           ## Mutation incidence

				HRAS.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HRAS.md]]

          +[[include:tables/table1_HRAS.md]]

           ## Warnings

				HRNR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HRNR.md]]

          +[[include:tables/table1_HRNR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				HSF2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_HSF2.md]]

          +[[include:tables/table1_HSF2.md]]

				HVCN1.md
			
          @@ -13,7 +13,7 @@ HVCN1, a voltage-gated proton channel, has been identified as recurrently mutate

           ## Relevance tier by entity

          -[[include:table1_HVCN1.md]]

          +[[include:tables/table1_HVCN1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ICK.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ICK.md]]

          +[[include:tables/table1_ICK.md]]

           ## Warnings

				ID3.md
			
          @@ -15,7 +15,7 @@ The existence of mutations in DLBCL were described in 2012 by Schmitz et al[@sch

           ## Relevance tier by entity

          -[[include:table1_ID3]]

          +[[include:tables/table1_ID3]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IDH1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IDH1.md]]

          +[[include:tables/table1_IDH1.md]]

				IER2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IER2.md]]

          +[[include:tables/table1_IER2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IFNGR1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IFNGR1.md]]

          +[[include:tables/table1_IFNGR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IGLL5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IGLL5]]

          +[[include:tables/table1_IGLL5]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IKBKB.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IKBKB.md]]

          +[[include:tables/table1_IKBKB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IKBKE.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_IKBKE.md]]

          +[[include:tables/table1_IKBKE.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IKZF3.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_IKZF3.md]]

          +[[include:tables/table1_IKZF3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IL13RA1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IL13RA1.md]]

          +[[include:tables/table1_IL13RA1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IL16.md
			
          @@ -12,7 +12,7 @@ The IL16 gene, which encodes a pro-inflammatory cytokine, plays a role in immune

           ## Relevance tier by entity

          -[[include:table1_IL16.md]]

          +[[include:tables/table1_IL16.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IL1RAPL2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IL1RAPL2.md]]

          +[[include:tables/table1_IL1RAPL2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IL4R.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_IL4R.md]]

          +[[include:tables/table1_IL4R.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IL6.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IL6.md]]

          +[[include:tables/table1_IL6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IL6ST.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IL6ST.md]]

          +[[include:tables/table1_IL6ST.md]]

				INO80.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_INO80.md]]

          +[[include:tables/table1_INO80.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				INSC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_INSC.md]]

          +[[include:tables/table1_INSC.md]]

				INTS6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_INTS6.md]]

          +[[include:tables/table1_INTS6.md]]

				IQGAP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IQGAP1.md]]

          +[[include:tables/table1_IQGAP1.md]]

				IQUB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IQUB.md]]

          +[[include:tables/table1_IQUB.md]]

				IRF1.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_IRF1.md]]

          +[[include:tables/table1_IRF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IRF2BP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_IRF2BP2.md]]

          +[[include:tables/table1_IRF2BP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IRF4.md
			
          @@ -16,7 +16,7 @@ There are a few mutation hotspots in this gene. The functional role of mutations

           ## Relevance tier by entity

          -[[include:table1_IRF4.md]]

          +[[include:tables/table1_IRF4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				IRF8.md
			
          @@ -21,7 +21,7 @@ Driver mutations affecting this gene in DLBCL/FL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_IRF8.md]]

          +[[include:tables/table1_IRF8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ITGA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ITGA2.md]]

          +[[include:tables/table1_ITGA2.md]]

				ITGA8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ITGA8.md]]

          +[[include:tables/table1_ITGA8.md]]

				ITGB3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ITGB3.md]]

          +[[include:tables/table1_ITGB3.md]]

				ITGB4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ITGB4.md]]

          +[[include:tables/table1_ITGB4.md]]

				ITPKB.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_ITPKB.md]]

          +[[include:tables/table1_ITPKB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ITPR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ITPR1.md]]

          +[[include:tables/table1_ITPR1.md]]

				ITPR3.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ITPR3.md]]

          +[[include:tables/table1_ITPR3.md]]

           ## Warnings

				JAG1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_JAG1.md]]

          +[[include:tables/table1_JAG1.md]]

				JAK1.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_JAK1.md]]

          +[[include:tables/table1_JAK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				JAK3.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_JAK3.md]]

          +[[include:tables/table1_JAK3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				JAKMIP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_JAKMIP2.md]]

          +[[include:tables/table1_JAKMIP2.md]]

				JUNB.md
			
          @@ -15,7 +15,7 @@ JUNB has been reported to be frequently mutated in T-cell/histiocyte-rich large 

           ## Relevance tier by entity

          -[[include:table1_JUNB.md]]

          +[[include:tables/table1_JUNB.md]]

           ## Warnings

				JUP.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[

           ## Relevance tier by entity

          -[[include:table1_JUP.md]]

          +[[include:tables/table1_JUP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KANK2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KANK2.md]]

          +[[include:tables/table1_KANK2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KAT6A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KAT6A.md]]

          +[[include:tables/table1_KAT6A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KCMF1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCMF1.md]]

          +[[include:tables/table1_KCMF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KCNA3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCNA3.md]]

          +[[include:tables/table1_KCNA3.md]]

				KCNAB3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCNAB3.md]]

          +[[include:tables/table1_KCNAB3.md]]

				KCNC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCNC2.md]]

          +[[include:tables/table1_KCNC2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KCNJ6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCNJ6.md]]

          +[[include:tables/table1_KCNJ6.md]]

				KCNK10.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCNK10.md]]

          +[[include:tables/table1_KCNK10.md]]

           ## Warnings

				KCNT2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KCNT2.md]]

          +[[include:tables/table1_KCNT2.md]]

				KDM2B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KDM2B.md]]

          +[[include:tables/table1_KDM2B.md]]

				KDM6A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KDM6A.md]]

          +[[include:tables/table1_KDM6A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KDR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KDR.md]]

          +[[include:tables/table1_KDR.md]]

				KIAA1614.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIAA1614.md]]

          +[[include:tables/table1_KIAA1614.md]]

				KIAA1671.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIAA1671.md]]

          +[[include:tables/table1_KIAA1671.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KIF1C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIF1C.md]]

          +[[include:tables/table1_KIF1C.md]]

				KIF21B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIF21B.md]]

          +[[include:tables/table1_KIF21B.md]]

				KIF26A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIF26A.md]]

          +[[include:tables/table1_KIF26A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KIFC3.md
			
          @@ -14,7 +14,7 @@ Due to [minimal support](KIFC3#representative-mutations) in the original primary

           ## Relevance tier by entity

          -[[include:table1_KIFC3.md]]

          +[[include:tables/table1_KIFC3.md]]

           ## Warnings

				KIR3DL1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIR3DL1.md]]

          +[[include:tables/table1_KIR3DL1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KIT.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KIT.md]]

          +[[include:tables/table1_KIT.md]]

				KITLG.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KITLG.md]]

          +[[include:tables/table1_KITLG.md]]

				KLB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KLB.md]]

          +[[include:tables/table1_KLB.md]]

				KLC3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KLC3.md]]

          +[[include:tables/table1_KLC3.md]]

				KLF2.md
			
          @@ -16,7 +16,7 @@ Contradictory to this, the mutation pattern in DLBCL implies selective pressure 

           ## Relevance tier by entity

          -[[include:table1_KLF2.md]]

          +[[include:tables/table1_KLF2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KLF4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KLF4.md]]

          +[[include:tables/table1_KLF4.md]]

				KLHL14.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_KLHL14.md]]

          +[[include:tables/table1_KLHL14.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KLHL21.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KLHL21.md]]

          +[[include:tables/table1_KLHL21.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KLHL26.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KLHL26.md]]

          +[[include:tables/table1_KLHL26.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KLHL6.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in DLBCL/FL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_KLHL6.md]]

          +[[include:tables/table1_KLHL6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KLRC4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KLRC4.md]]

          +[[include:tables/table1_KLRC4.md]]

				KMT2C.md
			
          @@ -14,7 +14,7 @@ This gene has been reported to be recurrently mutated in DLBCL. The rate of muta

           ## Relevance tier by entity

          -[[include:table1_KMT2C.md]]

          +[[include:tables/table1_KMT2C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KMT2D.md
			
          @@ -23,7 +23,7 @@ Driver mutations affecting this gene in BL/DLBCL/FL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_KMT2D]]

          +[[include:tables/table1_KMT2D]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KRAS.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_KRAS.md]]

          +[[include:tables/table1_KRAS.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				KRT6A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KRT6A.md]]

          +[[include:tables/table1_KRT6A.md]]

				KRTAP5-5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_KRTAP5-5.md]]

          +[[include:tables/table1_KRTAP5-5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LAMA5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LAMA5.md]]

          +[[include:tables/table1_LAMA5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LAPTM5.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by [Hübschm

           ## Relevance tier by entity

          -[[include:table1_LAPTM5.md]]

          +[[include:tables/table1_LAPTM5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LCOR.md
			
          @@ -13,7 +13,7 @@ LCOR (Ligand Dependent Nuclear Receptor Corepressor) is involved in the regulati

           ## Relevance tier by entity

          -[[include:table1_LCOR.md]]

          +[[include:tables/table1_LCOR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LEPR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LEPR.md]]

          +[[include:tables/table1_LEPR.md]]

				LEPREL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LEPREL1.md]]

          +[[include:tables/table1_LEPREL1.md]]

				LIFR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LIFR.md]]

          +[[include:tables/table1_LIFR.md]]

				LILRA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LILRA2.md]]

          +[[include:tables/table1_LILRA2.md]]

				LIMD2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LIMD2.md]]

          +[[include:tables/table1_LIMD2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LIN54.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LIN54.md]]

          +[[include:tables/table1_LIN54.md]]

           ## Warnings

				LIN7C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LIN7C.md]]

          +[[include:tables/table1_LIN7C.md]]

				LPHN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LPHN2.md]]

          +[[include:tables/table1_LPHN2.md]]

				LPHN3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LPHN3.md]]

          +[[include:tables/table1_LPHN3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LPP.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LPP.md]]

          +[[include:tables/table1_LPP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LRAP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRAP.md]]

          +[[include:tables/table1_LRAP.md]]

				LRIG3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRIG3.md]]

          +[[include:tables/table1_LRIG3.md]]

				LRP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRP1.md]]

          +[[include:tables/table1_LRP1.md]]

				LRP10.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRP10.md]]

          +[[include:tables/table1_LRP10.md]]

				LRP12.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_LRP12.md]]

          +[[include:tables/table1_LRP12.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LRP1B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRP1B.md]]

          +[[include:tables/table1_LRP1B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LRP3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRP3.md]]

          +[[include:tables/table1_LRP3.md]]

				LRRN3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LRRN3.md]]

          +[[include:tables/table1_LRRN3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LTB.md
			
          @@ -13,7 +13,7 @@ LTB (Lymphotoxin Beta) is a member of the tumor necrosis factor (TNF) superfamil

           ## Relevance tier by entity

          -[[include:table1_LTB.md]]

          +[[include:tables/table1_LTB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LUZP4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LUZP4.md]]

          +[[include:tables/table1_LUZP4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LYN.md
			
          @@ -12,7 +12,7 @@ LYN mutations have been reported in DLBCL but the rate is relatively rare in mos

           ## Relevance tier by entity

          -[[include:table1_LYN.md]]

          +[[include:tables/table1_LYN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				LYST.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_LYST.md]]

          +[[include:tables/table1_LYST.md]]

				MAGEC1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAGEC1.md]]

          +[[include:tables/table1_MAGEC1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MAGEC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAGEC2.md]]

          +[[include:tables/table1_MAGEC2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MAGEC3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAGEC3.md]]

          +[[include:tables/table1_MAGEC3.md]]

				MAGT1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAGT1.md]]

          +[[include:tables/table1_MAGT1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MALAT1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MALAT1.md]]

          +[[include:tables/table1_MALAT1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MAP2K1.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_MAP2K1.md]]

          +[[include:tables/table1_MAP2K1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MAP2K3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAP2K3.md]]

          +[[include:tables/table1_MAP2K3.md]]

				MAP3K14.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAP3K14.md]]

          +[[include:tables/table1_MAP3K14.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MAP3K6.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAP3K6.md]]

          +[[include:tables/table1_MAP3K6.md]]

           ## Warnings

				MAP4K4.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAP4K4.md]]

          +[[include:tables/table1_MAP4K4.md]]

           ## Warnings

				MAP7D1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MAP7D1.md]]

          +[[include:tables/table1_MAP7D1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MARCHF7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MARCHF7.md]]

          +[[include:tables/table1_MARCHF7.md]]

				MARK1.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MARK1.md]]

          +[[include:tables/table1_MARK1.md]]

           ## Warnings

				MBL2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MBL2.md]]

          +[[include:tables/table1_MBL2.md]]

				MCL1.md
			
          @@ -15,7 +15,7 @@ MCL1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) 

           ## Relevance tier by entity

          -[[include:table1_MCL1.md]]

          +[[include:tables/table1_MCL1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MCM8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MCM8.md]]

          +[[include:tables/table1_MCM8.md]]

				MCRS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MCRS1.md]]

          +[[include:tables/table1_MCRS1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MECOM.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MECOM.md]]

          +[[include:tables/table1_MECOM.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MED12L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MED12L.md]]

          +[[include:tables/table1_MED12L.md]]

				MED13L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MED13L.md]]

          +[[include:tables/table1_MED13L.md]]

				MEF2B.md
			
          @@ -16,7 +16,7 @@ Thus far, there is limited information about the consequence of MEF2B mutations 

           ## Relevance tier by entity

          -[[include:table1_MEF2B.md]]

          +[[include:tables/table1_MEF2B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MEF2C.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL by [Arthur et al](papers/ar

           ## Relevance tier by entity

          -[[include:table1_MEF2C.md]]

          +[[include:tables/table1_MEF2C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MET.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MET.md]]

          +[[include:tables/table1_MET.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MFHAS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MFHAS1.md]]

          +[[include:tables/table1_MFHAS1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MGA.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_MGA.md]]

          +[[include:tables/table1_MGA.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MGEA5.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_MGEA5.md]]

          +[[include:tables/table1_MGEA5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MIB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MIB1.md]]

          +[[include:tables/table1_MIB1.md]]

				MIR142.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_MIR142.md]]

          +[[include:tables/table1_MIR142.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MKI67.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MKI67.md]]

          +[[include:tables/table1_MKI67.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MLH1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MLH1.md]]

          +[[include:tables/table1_MLH1.md]]

				MME.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MME.md]]

          +[[include:tables/table1_MME.md]]

           ## Warnings

				MMEL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MMEL1.md]]

          +[[include:tables/table1_MMEL1.md]]

				MN1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MN1.md]]

          +[[include:tables/table1_MN1.md]]

				MORC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MORC2.md]]

          +[[include:tables/table1_MORC2.md]]

				MPDZ.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MPDZ.md]]

          +[[include:tables/table1_MPDZ.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MPEG1.md
			
          @@ -13,7 +13,7 @@ Mutations in MPEG1 have been described in DLBCL[@morinMutationalStructuralAnalys

           ## Relevance tier by entity

          -[[include:table1_MPEG1.md]]

          +[[include:tables/table1_MPEG1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MPL.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MPL.md]]

          +[[include:tables/table1_MPL.md]]

				MRGPRF.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MRGPRF.md]]

          +[[include:tables/table1_MRGPRF.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MS4A1.md
			
          @@ -20,7 +20,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_MS4A1.md]]

          +[[include:tables/table1_MS4A1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MSH2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MSH2.md]]

          +[[include:tables/table1_MSH2.md]]

           ## Warnings

				MSH6.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MSH6.md]]

          +[[include:tables/table1_MSH6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MSL2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MSL2.md]]

          +[[include:tables/table1_MSL2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MSN.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MSN.md]]

          +[[include:tables/table1_MSN.md]]

				MTMR3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MTMR3.md]]

          +[[include:tables/table1_MTMR3.md]]

				MTMR8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MTMR8.md]]

          +[[include:tables/table1_MTMR8.md]]

				MTOR.md
			
          @@ -20,7 +20,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_MTOR.md]]

          +[[include:tables/table1_MTOR.md]]

           ## Warnings

				MYB.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYB.md]]

          +[[include:tables/table1_MYB.md]]

           ## Warnings

				MYBPC2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYBPC2.md]]

          +[[include:tables/table1_MYBPC2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYC.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL/FL/BL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_MYC]]

          +[[include:tables/table1_MYC]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYCBP2.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[

           ## Relevance tier by entity

          -[[include:table1_MYCBP2.md]]

          +[[include:tables/table1_MYCBP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYD88.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_MYD88.md]]

          +[[include:tables/table1_MYD88.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYH10.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYH10.md]]

          +[[include:tables/table1_MYH10.md]]

           ## Warnings

				MYL7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYL7.md]]

          +[[include:tables/table1_MYL7.md]]

				MYLK.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYLK.md]]

          +[[include:tables/table1_MYLK.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYO18A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYO18A.md]]

          +[[include:tables/table1_MYO18A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYO19.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYO19.md]]

          +[[include:tables/table1_MYO19.md]]

				MYO1G.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYO1G.md]]

          +[[include:tables/table1_MYO1G.md]]

				MYO5C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYO5C.md]]

          +[[include:tables/table1_MYO5C.md]]

				MYOM2.md
			
          @@ -13,7 +13,7 @@ The prevalence of MYOM2 mutations in DLBCL varies across studies. The role of th

           ## Relevance tier by entity

          -[[include:table1_MYOM2.md]]

          +[[include:tables/table1_MYOM2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				MYRIP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_MYRIP.md]]

          +[[include:tables/table1_MYRIP.md]]

				NANOG.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NANOG.md]]

          +[[include:tables/table1_NANOG.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NAV1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NAV1.md]]

          +[[include:tables/table1_NAV1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NBEAL1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NBEAL1.md]]

          +[[include:tables/table1_NBEAL1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NCOA6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NCOA6.md]]

          +[[include:tables/table1_NCOA6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NCOR1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NCOR1.md]]

          +[[include:tables/table1_NCOR1.md]]

           ## Warnings

				NCOR2.md
			
          @@ -13,7 +13,7 @@ Mutations in this gene are relatively rare in DLBCL overall but show a pattern o

           ## Relevance tier by entity

          -[[include:table1_NCOR2.md]]

          +[[include:tables/table1_NCOR2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NDUFS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NDUFS1.md]]

          +[[include:tables/table1_NDUFS1.md]]

				NEAT1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NEAT1.md]]

          +[[include:tables/table1_NEAT1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NEB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NEB.md]]

          +[[include:tables/table1_NEB.md]]

				NEK1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NEK1.md]]

          +[[include:tables/table1_NEK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NELL2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NELL2.md]]

          +[[include:tables/table1_NELL2.md]]

				NF1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NF1.md]]

          +[[include:tables/table1_NF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NFIB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NFIB.md]]

          +[[include:tables/table1_NFIB.md]]

				NFKB2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NFKB2.md]]

          +[[include:tables/table1_NFKB2.md]]

           ## Warnings

				NFKBIA.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_NFKBIA.md]]

          +[[include:tables/table1_NFKBIA.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NFKBIE.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_NFKBIE.md]]

          +[[include:tables/table1_NFKBIE.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NFKBIZ.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_NFKBIZ.md]]

          +[[include:tables/table1_NFKBIZ.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NFX1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NFX1.md]]

          +[[include:tables/table1_NFX1.md]]

				NGFR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NGFR.md]]

          +[[include:tables/table1_NGFR.md]]

				NIN.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NIN.md]]

          +[[include:tables/table1_NIN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NIPBL.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NIPBL.md]]

          +[[include:tables/table1_NIPBL.md]]

				NLGN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NLGN2.md]]

          +[[include:tables/table1_NLGN2.md]]

				NLRP5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NLRP5.md]]

          +[[include:tables/table1_NLRP5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NLRP7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NLRP7.md]]

          +[[include:tables/table1_NLRP7.md]]

				NLRP8.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NLRP8.md]]

          +[[include:tables/table1_NLRP8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NOA1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NOA1.md]]

          +[[include:tables/table1_NOA1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NOL9.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NOL9.md]]

          +[[include:tables/table1_NOL9.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NOTCH1.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_NOTCH1.md]]

          +[[include:tables/table1_NOTCH1.md]]

           ## Warnings

				NOTCH2.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_NOTCH2.md]]

          +[[include:tables/table1_NOTCH2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NOTCH3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NOTCH3.md]]

          +[[include:tables/table1_NOTCH3.md]]

				NPHP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NPHP1.md]]

          +[[include:tables/table1_NPHP1.md]]

				NPY2R.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NPY2R.md]]

          +[[include:tables/table1_NPY2R.md]]

				NR2F2.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a

           ## Relevance tier by entity

          -[[include:table1_NR2F2.md]]

          +[[include:tables/table1_NR2F2.md]]

           ## Warnings

				NRAS.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NRAS.md]]

          +[[include:tables/table1_NRAS.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NRXN2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NRXN2.md]]

          +[[include:tables/table1_NRXN2.md]]

           ## Warnings

				NSD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NSD1.md]]

          +[[include:tables/table1_NSD1.md]]

				NSD2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NSD2.md]]

          +[[include:tables/table1_NSD2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				NUP153.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NUP153.md]]

          +[[include:tables/table1_NUP153.md]]

				NUP214.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_NUP214.md]]

          +[[include:tables/table1_NUP214.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ODZ2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ODZ2.md]]

          +[[include:tables/table1_ODZ2.md]]

				ODZ3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ODZ3.md]]

          +[[include:tables/table1_ODZ3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				OFD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_OFD1.md]]

          +[[include:tables/table1_OFD1.md]]

				OGDHL.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_OGDHL.md]]

          +[[include:tables/table1_OGDHL.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ONECUT1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ONECUT1.md]]

          +[[include:tables/table1_ONECUT1.md]]

				OR13C2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_OR13C2.md]]

          +[[include:tables/table1_OR13C2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				OR6K3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_OR6K3.md]]

          +[[include:tables/table1_OR6K3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				OR8H2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_OR8H2.md]]

          +[[include:tables/table1_OR8H2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				OSBPL10.md
			
          @@ -13,7 +13,7 @@ OSBPL10 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ash

           ## Relevance tier by entity

          -[[include:table1_OSBPL10.md]]

          +[[include:tables/table1_OSBPL10.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				P2RX5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_P2RX5.md]]

          +[[include:tables/table1_P2RX5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				P2RY2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_P2RY2.md]]

          +[[include:tables/table1_P2RY2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				P2RY8.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in BL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_P2RY8.md]]

          +[[include:tables/table1_P2RY8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PABPC1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PABPC1.md]]

          +[[include:tables/table1_PABPC1.md]]

				PABPC4L.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PABPC4L.md]]

          +[[include:tables/table1_PABPC4L.md]]

           ## Warnings

				PACRG.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PACRG.md]]

          +[[include:tables/table1_PACRG.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PADI1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PADI1.md]]

          +[[include:tables/table1_PADI1.md]]

				PAPOLG.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PAPOLG.md]]

          +[[include:tables/table1_PAPOLG.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PAPPA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PAPPA2.md]]

          +[[include:tables/table1_PAPPA2.md]]

				PARK2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PARK2.md]]

          +[[include:tables/table1_PARK2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PASD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PASD1.md]]

          +[[include:tables/table1_PASD1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PASK.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PASK.md]]

          +[[include:tables/table1_PASK.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PAX5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PAX5.md]]

          +[[include:tables/table1_PAX5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PBX1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PBX1.md]]

          +[[include:tables/table1_PBX1.md]]

				PC.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PC.md]]

          +[[include:tables/table1_PC.md]]

           ## Warnings

				PCBP1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCBP1]]

          +[[include:tables/table1_PCBP1]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PCCB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCCB.md]]

          +[[include:tables/table1_PCCB.md]]

				PCDE1C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDE1C.md]]

          +[[include:tables/table1_PCDE1C.md]]

				PCDH7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDH7.md]]

          +[[include:tables/table1_PCDH7.md]]

				PCDHA11.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHA11.md]]

          +[[include:tables/table1_PCDHA11.md]]

           ## Warnings

				PCDHB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB1.md]]

          +[[include:tables/table1_PCDHB1.md]]

				PCDHB11.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB11.md]]

          +[[include:tables/table1_PCDHB11.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PCDHB15.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB15.md]]

          +[[include:tables/table1_PCDHB15.md]]

				PCDHB2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB2.md]]

          +[[include:tables/table1_PCDHB2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PCDHB3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB3.md]]

          +[[include:tables/table1_PCDHB3.md]]

				PCDHB5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB5.md]]

          +[[include:tables/table1_PCDHB5.md]]

				PCDHB6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHB6.md]]

          +[[include:tables/table1_PCDHB6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PCDHGA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCDHGA2.md]]

          +[[include:tables/table1_PCDHGA2.md]]

				PCLO.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCLO.md]]

          +[[include:tables/table1_PCLO.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PCSK2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PCSK2.md]]

          +[[include:tables/table1_PCSK2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PDCD11.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDCD11.md]]

          +[[include:tables/table1_PDCD11.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PDE1C.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDE1C.md]]

          +[[include:tables/table1_PDE1C.md]]

				PDE4DIP.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDE4DIP.md]]

          +[[include:tables/table1_PDE4DIP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PDGFC.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDGFC.md]]

          +[[include:tables/table1_PDGFC.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PDGFRA.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDGFRA.md]]

          +[[include:tables/table1_PDGFRA.md]]

				PDGFRB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDGFRB.md]]

          +[[include:tables/table1_PDGFRB.md]]

				PDIA2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDIA2.md]]

          +[[include:tables/table1_PDIA2.md]]

				PDLIM3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDLIM3.md]]

          +[[include:tables/table1_PDLIM3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PDS5B.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDS5B.md]]

          +[[include:tables/table1_PDS5B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PDZRN3.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDZRN3.md]]

          +[[include:tables/table1_PDZRN3.md]]

           ## Warnings

				PDZRN4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PDZRN4.md]]

          +[[include:tables/table1_PDZRN4.md]]

				PFN1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PFN1.md]]

          +[[include:tables/table1_PFN1.md]]

				PGR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PGR.md]]

          +[[include:tables/table1_PGR.md]]

				PHF6.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PHF6.md]]

          +[[include:tables/table1_PHF6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PIK3CD.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PIK3CD.md]]

          +[[include:tables/table1_PIK3CD.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PIK3R1.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_PIK3R1.md]]

          +[[include:tables/table1_PIK3R1.md]]

           ## Warnings

				PIM1.md
			
          @@ -21,7 +21,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_PIM1.md]]

          +[[include:tables/table1_PIM1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PIM2.md
			
          @@ -14,7 +14,7 @@ PIM2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) 

           ## Relevance tier by entity

          -[[include:table1_PIM2.md]]

          +[[include:tables/table1_PIM2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PKD1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PKD1.md]]

          +[[include:tables/table1_PKD1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PLA2G4B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PLA2G4B.md]]

          +[[include:tables/table1_PLA2G4B.md]]

				PLA2G4D.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PLA2G4D.md]]

          +[[include:tables/table1_PLA2G4D.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PLCB4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PLCB4.md]]

          +[[include:tables/table1_PLCB4.md]]

				PLCG2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PLCG2.md]]

          +[[include:tables/table1_PLCG2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PLEKHA7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PLEKHA7.md]]

          +[[include:tables/table1_PLEKHA7.md]]

				PLXNB3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PLXNB3.md]]

          +[[include:tables/table1_PLXNB3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PMS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PMS1.md]]

          +[[include:tables/table1_PMS1.md]]

				PNLIPRP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PNLIPRP1.md]]

          +[[include:tables/table1_PNLIPRP1.md]]

				PNPO.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_PNPO.md]]

          +[[include:tables/table1_PNPO.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PNPT1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PNPT1.md]]

          +[[include:tables/table1_PNPT1.md]]

				POGZ.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POGZ.md]]

          +[[include:tables/table1_POGZ.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				POLD3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POLD3.md]]

          +[[include:tables/table1_POLD3.md]]

				POLE.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POLE.md]]

          +[[include:tables/table1_POLE.md]]

				POLQ.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POLQ.md]]

          +[[include:tables/table1_POLQ.md]]

				POLRMT.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POLRMT.md]]

          +[[include:tables/table1_POLRMT.md]]

           ## Warnings

				POR.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POR.md]]

          +[[include:tables/table1_POR.md]]

           ## Warnings

				POT1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_POT1.md]]

          +[[include:tables/table1_POT1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				POU2AF1.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_POU2AF1.md]]

          +[[include:tables/table1_POU2AF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				POU2F2.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_POU2F2.md]]

          +[[include:tables/table1_POU2F2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PPARGC1A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PPARGC1A.md]]

          +[[include:tables/table1_PPARGC1A.md]]

				PPP2R2B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PPP2R2B.md]]

          +[[include:tables/table1_PPP2R2B.md]]

				PPP2R5A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PPP2R5A.md]]

          +[[include:tables/table1_PPP2R5A.md]]

				PPP4C.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PPP4C.md]]

          +[[include:tables/table1_PPP4C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PPP6R2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PPP6R2.md]]

          +[[include:tables/table1_PPP6R2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PPWD1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PPWD1.md]]

          +[[include:tables/table1_PPWD1.md]]

				PRDM1.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_PRDM1.md]]

          +[[include:tables/table1_PRDM1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PRDM16.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRDM16.md]]

          +[[include:tables/table1_PRDM16.md]]

				PREX1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PREX1.md]]

          +[[include:tables/table1_PREX1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PRKCB.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRKCB.md]]

          +[[include:tables/table1_PRKCB.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PRKCB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRKCB1.md]]

          +[[include:tables/table1_PRKCB1.md]]

				PRKCQ.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRKCQ.md]]

          +[[include:tables/table1_PRKCQ.md]]

				PRKDC.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRKDC.md]]

          +[[include:tables/table1_PRKDC.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PROS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PROS1.md]]

          +[[include:tables/table1_PROS1.md]]

				PRPS1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRPS1.md]]

          +[[include:tables/table1_PRPS1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PRSS22.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](PRSS22#representative-mutation) in the original primary

           ## Relevance tier by entity

          -[[include:table1_PRSS22.md]]

          +[[include:tables/table1_PRSS22.md]]

           ## Warnings

				PRSS7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRSS7.md]]

          +[[include:tables/table1_PRSS7.md]]

				PRUNE2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PRUNE2.md]]

          +[[include:tables/table1_PRUNE2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PTCH1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTCH1.md]]

          +[[include:tables/table1_PTCH1.md]]

				PTEN.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in BL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_PTEN.md]]

          +[[include:tables/table1_PTEN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PTPN1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPN1.md]]

          +[[include:tables/table1_PTPN1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PTPN14.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPN14.md]]

          +[[include:tables/table1_PTPN14.md]]

				PTPN21.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPN21.md]]

          +[[include:tables/table1_PTPN21.md]]

				PTPN23.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPN23.md]]

          +[[include:tables/table1_PTPN23.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PTPN6.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_PTPN6.md]]

          +[[include:tables/table1_PTPN6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PTPRD.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPRD.md]]

          +[[include:tables/table1_PTPRD.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				PTPRF.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPRF.md]]

          +[[include:tables/table1_PTPRF.md]]

				PTPRK.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPRK.md]]

          +[[include:tables/table1_PTPRK.md]]

           ## Warnings

				PTPRN.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPRN.md]]

          +[[include:tables/table1_PTPRN.md]]

           ## Warnings

				PTPRT.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PTPRT.md]]

          +[[include:tables/table1_PTPRT.md]]

				PXDNL.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PXDNL.md]]

          +[[include:tables/table1_PXDNL.md]]

           ## Warnings

				PXK.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PXK.md]]

          +[[include:tables/table1_PXK.md]]

				PZP.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_PZP.md]]

          +[[include:tables/table1_PZP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RAB3GAP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAB3GAP1.md]]

          +[[include:tables/table1_RAB3GAP1.md]]

				RAC2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAC2.md]]

          +[[include:tables/table1_RAC2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RAD9A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAD9A.md]]

          +[[include:tables/table1_RAD9A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RAF1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAF1.md]]

          +[[include:tables/table1_RAF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RANBP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RANBP2.md]]

          +[[include:tables/table1_RANBP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RANBP6.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RANBP6.md]]

          +[[include:tables/table1_RANBP6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RAPGEF1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAPGEF1.md]]

          +[[include:tables/table1_RAPGEF1.md]]

				RAPGEF2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAPGEF2.md]]

          +[[include:tables/table1_RAPGEF2.md]]

				RAPGEF3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RAPGEF3.md]]

          +[[include:tables/table1_RAPGEF3.md]]

				RARA.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RARA.md]]

          +[[include:tables/table1_RARA.md]]

           ## Warnings

				RASGEF1A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RASGEF1A.md]]

          +[[include:tables/table1_RASGEF1A.md]]

				RB1.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_RB1.md]]

          +[[include:tables/table1_RB1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RBM15B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RBM15B.md]]

          +[[include:tables/table1_RBM15B.md]]

				RBM38.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RBM38.md]]

          +[[include:tables/table1_RBM38.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RBM6.md
			
          @@ -14,7 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma

           ## Relevance tier by entity

          -[[include:table1_RBM6.md]]

          +[[include:tables/table1_RBM6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RBP3.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RBP3.md]]

          +[[include:tables/table1_RBP3.md]]

           ## Warnings

				RCOR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RCOR1.md]]

          +[[include:tables/table1_RCOR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RECQL4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RECQL4.md]]

          +[[include:tables/table1_RECQL4.md]]

				RELN.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RELN.md]]

          +[[include:tables/table1_RELN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RET.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](RET#representative-mutation) in the original primary da

           ## Relevance tier by entity

          -[[include:table1_RET.md]]

          +[[include:tables/table1_RET.md]]

           ## Warnings

				REV3L.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_REV3L.md]]

          +[[include:tables/table1_REV3L.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RFC1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RFC1.md]]

          +[[include:tables/table1_RFC1.md]]

				RFTN1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RFTN1.md]]

          +[[include:tables/table1_RFTN1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RFX7.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in DLBCL/BL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_RFX7.md]]

          +[[include:tables/table1_RFX7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RGAG1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RGAG1.md]]

          +[[include:tables/table1_RGAG1.md]]

				RGS1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RGS1.md]]

          +[[include:tables/table1_RGS1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RGS4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RGS4.md]]

          +[[include:tables/table1_RGS4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RHEX.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RHEX.md]]

          +[[include:tables/table1_RHEX.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RHOA.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL/BL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_RHOA.md]]

          +[[include:tables/table1_RHOA.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RHOH.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RHOH.md]]

          +[[include:tables/table1_RHOH.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RHPN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RHPN2.md]]

          +[[include:tables/table1_RHPN2.md]]

				RIF1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RIF1.md]]

          +[[include:tables/table1_RIF1.md]]

				RIMS4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RIMS4.md]]

          +[[include:tables/table1_RIMS4.md]]

				RNF144B.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RNF144B.md]]

          +[[include:tables/table1_RNF144B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ROBO2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ROBO2.md]]

          +[[include:tables/table1_ROBO2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ROCK1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ROCK1.md]]

          +[[include:tables/table1_ROCK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ROR2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ROR2.md]]

          +[[include:tables/table1_ROR2.md]]

				RPL10.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RPL10.md]]

          +[[include:tables/table1_RPL10.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RPL1L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RPL1L.md]]

          +[[include:tables/table1_RPL1L.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RPTOR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RPTOR.md]]

          +[[include:tables/table1_RPTOR.md]]

				RRAGC.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL/FL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_RRAGC.md]]

          +[[include:tables/table1_RRAGC.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				RSL1D1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RSL1D1.md]]

          +[[include:tables/table1_RSL1D1.md]]

				RUNDC1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RUNDC1.md]]

          +[[include:tables/table1_RUNDC1.md]]

				RUNX1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RUNX1.md]]

          +[[include:tables/table1_RUNX1.md]]

           ## Warnings

				RYR1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_RYR1.md]]

          +[[include:tables/table1_RYR1.md]]

				S1PR1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_S1PR1.md]]

          +[[include:tables/table1_S1PR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				S1PR2.md
			
          @@ -17,7 +17,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_S1PR2.md]]

          +[[include:tables/table1_S1PR2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SAL3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SAL3.md]]

          +[[include:tables/table1_SAL3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SALL3.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SALL3.md]]

          +[[include:tables/table1_SALL3.md]]

           ## Warnings

				SAMD5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SAMD5.md]]

          +[[include:tables/table1_SAMD5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SAMD9L.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SAMD9L.md]]

          +[[include:tables/table1_SAMD9L.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SAPS2.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SAPS2.md]]

          +[[include:tables/table1_SAPS2.md]]

           ## Warnings

				SAPS3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SAPS3.md]]

          +[[include:tables/table1_SAPS3.md]]

				SARM1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SARM1.md]]

          +[[include:tables/table1_SARM1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SBF1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SBF1.md]]

          +[[include:tables/table1_SBF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SCG3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SCG3.md]]

          +[[include:tables/table1_SCG3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SCYL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SCYL1.md]]

          +[[include:tables/table1_SCYL1.md]]

				SDK2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SDK2.md]]

          +[[include:tables/table1_SDK2.md]]

				SEC14L5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SEC14L5.md]]

          +[[include:tables/table1_SEC14L5.md]]

				SEL1L3.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SEL1L3.md]]

          +[[include:tables/table1_SEL1L3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SEMA3A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SEMA3A.md]]

          +[[include:tables/table1_SEMA3A.md]]

				SEMA3D.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SEMA3D.md]]

          +[[include:tables/table1_SEMA3D.md]]

				SEMA5A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SEMA5A.md]]

          +[[include:tables/table1_SEMA5A.md]]

				SENP7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SENP7.md]]

          +[[include:tables/table1_SENP7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SERINC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SERINC2.md]]

          +[[include:tables/table1_SERINC2.md]]

				SERPINA1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SERPINA1.md]]

          +[[include:tables/table1_SERPINA1.md]]

				SERPINA9.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SERPINA9.md]]

          +[[include:tables/table1_SERPINA9.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SETD1B.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_SETD1B.md]]

          +[[include:tables/table1_SETD1B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SETD2.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_SETD2.md]]

          +[[include:tables/table1_SETD2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SETD5.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SETD5.md]]

          +[[include:tables/table1_SETD5.md]]

           ## Warnings

				SETDB1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SETDB1.md]]

          +[[include:tables/table1_SETDB1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SF3B1.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_SF3B1.md]]

          +[[include:tables/table1_SF3B1.md]]

           ## Warnings

				SGK1.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_SGK1.md]]

          +[[include:tables/table1_SGK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SH3PXD2B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SH3PXD2B.md]]

          +[[include:tables/table1_SH3PXD2B.md]]

				SHANK1.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SHANK1.md]]

          +[[include:tables/table1_SHANK1.md]]

           ## Warnings

				SHMT2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SHMT2.md]]

          +[[include:tables/table1_SHMT2.md]]

				SHROOM3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SHROOM3.md]]

          +[[include:tables/table1_SHROOM3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SI.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SI.md]]

          +[[include:tables/table1_SI.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SIAH2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SIAH2.md]]

          +[[include:tables/table1_SIAH2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SIGLEC10.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SIGLEC10.md]]

          +[[include:tables/table1_SIGLEC10.md]]

				SIN3A.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SIN3A.md]]

          +[[include:tables/table1_SIN3A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SLC16A7.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC16A7.md]]

          +[[include:tables/table1_SLC16A7.md]]

				SLC16A8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC16A8.md]]

          +[[include:tables/table1_SLC16A8.md]]

				SLC17A6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC17A6.md]]

          +[[include:tables/table1_SLC17A6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SLC29A2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC29A2.md]]

          +[[include:tables/table1_SLC29A2.md]]

           ## Warnings

				SLC34A2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC34A2.md]]

          +[[include:tables/table1_SLC34A2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SLC38A8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC38A8.md]]

          +[[include:tables/table1_SLC38A8.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SLC4A8.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC4A8.md]]

          +[[include:tables/table1_SLC4A8.md]]

				SLC5A1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC5A1.md]]

          +[[include:tables/table1_SLC5A1.md]]

				SLC9A5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLC9A5.md]]

          +[[include:tables/table1_SLC9A5.md]]

				SLITRK6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SLITRK6.md]]

          +[[include:tables/table1_SLITRK6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SMARCA1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SMARCA1.md]]

          +[[include:tables/table1_SMARCA1.md]]

				SMARCA4.md
			
          @@ -20,7 +20,7 @@ Driver mutations affecting this gene in DLBCL/FL/BL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_SMARCA4.md]]

          +[[include:tables/table1_SMARCA4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SMARCB1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SMARCB1.md]]

          +[[include:tables/table1_SMARCB1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SMC1A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SMC1A.md]]

          +[[include:tables/table1_SMC1A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SMEK1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SMEK1.md]]

          +[[include:tables/table1_SMEK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SMO.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SMO.md]]

          +[[include:tables/table1_SMO.md]]

				SNTB2.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SNTB2.md]]

          +[[include:tables/table1_SNTB2.md]]

           ## Warnings

				SOCS1.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_SOCS1.md]]

          +[[include:tables/table1_SOCS1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SOS2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SOS2.md]]

          +[[include:tables/table1_SOS2.md]]

				SOX6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SOX6.md]]

          +[[include:tables/table1_SOX6.md]]

				SP140.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SP140.md]]

          +[[include:tables/table1_SP140.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SPEG.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SPEG.md]]

          +[[include:tables/table1_SPEG.md]]

				SPEN.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SPEN.md]]

          +[[include:tables/table1_SPEN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SPTBN1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SPTBN1.md]]

          +[[include:tables/table1_SPTBN1.md]]

				SRPX.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SRPX.md]]

          +[[include:tables/table1_SRPX.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SRRM2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SRRM2.md]]

          +[[include:tables/table1_SRRM2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ST6GAL1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ST6GAL1.md]]

          +[[include:tables/table1_ST6GAL1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ST8SIA3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ST8SIA3.md]]

          +[[include:tables/table1_ST8SIA3.md]]

				STAB2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_STAB2.md]]

          +[[include:tables/table1_STAB2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				STAT3.md
			
          @@ -16,7 +16,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_STAT3.md]]

          +[[include:tables/table1_STAT3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				STAT5B.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_STAT5B.md]]

          +[[include:tables/table1_STAT5B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				STAT6.md
			
          @@ -19,7 +19,7 @@ Driver mutations affecting this gene in DLBCL/FL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_STAT6.md]]

          +[[include:tables/table1_STAT6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				STXBP5.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_STXBP5.md]]

          +[[include:tables/table1_STXBP5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SULF2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SULF2.md]]

          +[[include:tables/table1_SULF2.md]]

				SWAP70.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SWAP70.md]]

          +[[include:tables/table1_SWAP70.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SYN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SYN2.md]]

          +[[include:tables/table1_SYN2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SYNE1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SYNE1.md]]

          +[[include:tables/table1_SYNE1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				SYNGAP1.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](SYNGAP1#representative-mutation) in the original primar

           ## Relevance tier by entity

          -[[include:table1_SYNGAP1.md]]

          +[[include:tables/table1_SYNGAP1.md]]

           ## Warnings

				SYPL1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_SYPL1.md]]

          +[[include:tables/table1_SYPL1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TAF1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TAF1.md]]

          +[[include:tables/table1_TAF1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TAF1L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TAF1L.md]]

          +[[include:tables/table1_TAF1L.md]]

				TAF4B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TAF4B.md]]

          +[[include:tables/table1_TAF4B.md]]

				TAP1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TAP1.md]]

          +[[include:tables/table1_TAP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TBC1D15.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBC1D15.md]]

          +[[include:tables/table1_TBC1D15.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TBC1D26.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBC1D26.md]]

          +[[include:tables/table1_TBC1D26.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TBC1D3F.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBC1D3F.md]]

          +[[include:tables/table1_TBC1D3F.md]]

				TBC1D4.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBC1D4.md]]

          +[[include:tables/table1_TBC1D4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TBC1D9B.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBC1D9B.md]]

          +[[include:tables/table1_TBC1D9B.md]]

           ## Warnings

				TBK1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBK1.md]]

          +[[include:tables/table1_TBK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TBL1XR1.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_TBL1XR1.md]]

          +[[include:tables/table1_TBL1XR1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TBP.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TBP.md]]

          +[[include:tables/table1_TBP.md]]

				TCF3.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in BL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_TCF3.md]]

          +[[include:tables/table1_TCF3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TCL1A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TCL1A.md]]

          +[[include:tables/table1_TCL1A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TCTN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TCTN2.md]]

          +[[include:tables/table1_TCTN2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TECRL.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TECRL.md]]

          +[[include:tables/table1_TECRL.md]]

				TERT.md
			
          @@ -13,7 +13,7 @@ Non-coding mutations in the promoter of this gene have been described in MCL.

           ## Relevance tier by entity

          -[[include:table1_TERT.md]]

          +[[include:tables/table1_TERT.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TET2.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_TET2.md]]

          +[[include:tables/table1_TET2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TFAP4.md
			
          @@ -18,7 +18,7 @@ Driver mutations affecting this gene in BL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_TFAP4.md]]

          +[[include:tables/table1_TFAP4.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TGFBR2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TGFBR2.md]]

          +[[include:tables/table1_TGFBR2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				THBS4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_THBS4.md]]

          +[[include:tables/table1_THBS4.md]]

				TICRR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TICRR.md]]

          +[[include:tables/table1_TICRR.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TIGD6.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TIGD6.md]]

          +[[include:tables/table1_TIGD6.md]]

           ## Warnings

				TIMM50.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TIMM50.md]]

          +[[include:tables/table1_TIMM50.md]]

				TIPARP.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TIPARP.md]]

          +[[include:tables/table1_TIPARP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TLL2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TLL2.md]]

          +[[include:tables/table1_TLL2.md]]

				TLN1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TLN1.md]]

          +[[include:tables/table1_TLN1.md]]

				TLN2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TLN2.md]]

          +[[include:tables/table1_TLN2.md]]

				TLR2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TLR2.md]]

          +[[include:tables/table1_TLR2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TLR4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TLR4.md]]

          +[[include:tables/table1_TLR4.md]]

				TMC1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TMC1.md]]

          +[[include:tables/table1_TMC1.md]]

				TMEM161A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TMEM161A.md]]

          +[[include:tables/table1_TMEM161A.md]]

				TMEM16E.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TMEM16E.md]]

          +[[include:tables/table1_TMEM16E.md]]

				TMEM30A.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_TMEM30A.md]]

          +[[include:tables/table1_TMEM30A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TMEM63A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TMEM63A.md]]

          +[[include:tables/table1_TMEM63A.md]]

				TMSB4X.md
			
          @@ -14,7 +14,7 @@ TMSB4X is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm

           ## Relevance tier by entity

          -[[include:table1_TMSB4X.md]]

          +[[include:tables/table1_TMSB4X.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TMSL3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TMSL3.md]]

          +[[include:tables/table1_TMSL3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TNF.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TNF.md]]

          +[[include:tables/table1_TNF.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TNFAIP3.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in FL/DLBCL have been experimentally demons

           ## Relevance tier by entity

          -[[include:table1_TNFAIP3.md]]

          +[[include:tables/table1_TNFAIP3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TNFRSF14.md
			
          @@ -16,7 +16,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_TNFRSF14.md]]

          +[[include:tables/table1_TNFRSF14.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TNIP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TNIP1.md]]

          +[[include:tables/table1_TNIP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TNIP2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TNIP2.md]]

          +[[include:tables/table1_TNIP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TNPO1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TNPO1.md]]

          +[[include:tables/table1_TNPO1.md]]

				TNRC6B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TNRC6B.md]]

          +[[include:tables/table1_TNRC6B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TOP2A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TOP2A.md]]

          +[[include:tables/table1_TOP2A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TOX.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TOX.md]]

          +[[include:tables/table1_TOX.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TP53.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in BL/FL/DLBCL have been experimentally dem

           ## Relevance tier by entity

          -[[include:table1_TP53.md]]

          +[[include:tables/table1_TP53.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TPP1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TPP1.md]]

          +[[include:tables/table1_TPP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TPR.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TPR.md]]

          +[[include:tables/table1_TPR.md]]

				TPRKB.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TPRKB.md]]

          +[[include:tables/table1_TPRKB.md]]

				TPST2.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TPST2.md]]

          +[[include:tables/table1_TPST2.md]]

           ## Warnings

				TPTE.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TPTE.md]]

          +[[include:tables/table1_TPTE.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TRAF3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRAF3.md]]

          +[[include:tables/table1_TRAF3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TRAF6.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRAF6.md]]

          +[[include:tables/table1_TRAF6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TRIM2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRIM2.md]]

          +[[include:tables/table1_TRIM2.md]]

				TRIM37.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRIM37.md]]

          +[[include:tables/table1_TRIM37.md]]

				TRIP11.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRIP11.md]]

          +[[include:tables/table1_TRIP11.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TRPM6.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRPM6.md]]

          +[[include:tables/table1_TRPM6.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TRRAP.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TRRAP.md]]

          +[[include:tables/table1_TRRAP.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TSC2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TSC2.md]]

          +[[include:tables/table1_TSC2.md]]

				TSC22D1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TSC22D1.md]]

          +[[include:tables/table1_TSC22D1.md]]

				TSHZ2.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TSHZ2.md]]

          +[[include:tables/table1_TSHZ2.md]]

				TTN.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TTN.md]]

          +[[include:tables/table1_TTN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				TYRO3.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_TYRO3.md]]

          +[[include:tables/table1_TYRO3.md]]

				UBE2A.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UBE2A.md]]

          +[[include:tables/table1_UBE2A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				UBE2J1.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UBE2J1.md]]

          +[[include:tables/table1_UBE2J1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				UBR5.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_UBR5.md]]

          +[[include:tables/table1_UBR5.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				UBXN11.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UBXN11.md]]

          +[[include:tables/table1_UBXN11.md]]

				UBXN2B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UBXN2B.md]]

          +[[include:tables/table1_UBXN2B.md]]

				UHRF1BP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UHRF1BP1.md]]

          +[[include:tables/table1_UHRF1BP1.md]]

				UHRF1BP1L.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UHRF1BP1L.md]]

          +[[include:tables/table1_UHRF1BP1L.md]]

				UNC13B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UNC13B.md]]

          +[[include:tables/table1_UNC13B.md]]

				UNC5B.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UNC5B.md]]

          +[[include:tables/table1_UNC5B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				UNC5C.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UNC5C.md]]

          +[[include:tables/table1_UNC5C.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				UNC5D.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UNC5D.md]]

          +[[include:tables/table1_UNC5D.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				UQCRC1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_UQCRC1.md]]

          +[[include:tables/table1_UQCRC1.md]]

				USH2A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_USH2A.md]]

          +[[include:tables/table1_USH2A.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				USP7.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_USP7.md]]

          +[[include:tables/table1_USP7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				VANGL1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_VANGL1.md]]

          +[[include:tables/table1_VANGL1.md]]

				VAX1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_VAX1.md]]

          +[[include:tables/table1_VAX1.md]]

				VMA21.md
			
          @@ -13,7 +13,7 @@ Driver mutations affecting this gene in FL have been experimentally demonstrated

           ## Relevance tier by entity

          -[[include:table1_VMA21.md]]

          +[[include:tables/table1_VMA21.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				VMP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_VMP1.md]]

          +[[include:tables/table1_VMP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				VPS13A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_VPS13A.md]]

          +[[include:tables/table1_VPS13A.md]]

				VPS13B.md
			
          @@ -9,7 +9,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_VPS13B.md]]

          +[[include:tables/table1_VPS13B.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				VWA7.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_VWA7.md]]

          +[[include:tables/table1_VWA7.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WAC.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WAC.md]]

          +[[include:tables/table1_WAC.md]]

           ## Warnings

				WDFY3.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDFY3.md]]

          +[[include:tables/table1_WDFY3.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WDR65.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDR65.md]]

          +[[include:tables/table1_WDR65.md]]

				WDR66.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDR66.md]]

          +[[include:tables/table1_WDR66.md]]

				WDR67.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDR67.md]]

          +[[include:tables/table1_WDR67.md]]

				WDR7.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDR7.md]]

          +[[include:tables/table1_WDR7.md]]

           ## Warnings

				WDR87.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDR87.md]]

          +[[include:tables/table1_WDR87.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WDR90.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WDR90.md]]

          +[[include:tables/table1_WDR90.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WEE1.md
			
          @@ -13,7 +13,7 @@ WEE1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm) 

           ## Relevance tier by entity

          -[[include:table1_WEE1.md]]

          +[[include:tables/table1_WEE1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WHAMM.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WHAMM.md]]

          +[[include:tables/table1_WHAMM.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WIF1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WIF1.md]]

          +[[include:tables/table1_WIF1.md]]

				WNK1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WNK1.md]]

          +[[include:tables/table1_WNK1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WNK2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WNK2.md]]

          +[[include:tables/table1_WNK2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				WNK4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WNK4.md]]

          +[[include:tables/table1_WNK4.md]]

				WT1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_WT1.md]]

          +[[include:tables/table1_WT1.md]]

				XDH.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_XDH.md]]

          +[[include:tables/table1_XDH.md]]

				XIRP2.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_XIRP2.md]]

          +[[include:tables/table1_XIRP2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				XPO1.md
			
          @@ -15,7 +15,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_XPO1.md]]

          +[[include:tables/table1_XPO1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				YY1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_YY1.md]]

          +[[include:tables/table1_YY1.md]]

           ## Warnings

				YY1AP1.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_YY1AP1.md]]

          +[[include:tables/table1_YY1AP1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZAN.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZAN.md]]

          +[[include:tables/table1_ZAN.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZBTB7A.md
			
          @@ -12,7 +12,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZBTB7A.md]]

          +[[include:tables/table1_ZBTB7A.md]]

           ## Warnings

				ZC3H12A.md
			
          @@ -14,7 +14,7 @@ Driver mutations affecting this gene in DLBCL have been experimentally demonstra

           ## Relevance tier by entity

          -[[include:table1_ZC3H12A]]

          +[[include:tables/table1_ZC3H12A]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZCCHC11.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZCCHC11.md]]

          +[[include:tables/table1_ZCCHC11.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZCCHC7.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZCCHC7]]

          +[[include:tables/table1_ZCCHC7]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZEB2.md
			
          @@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero

           ## Relevance tier by entity

          -[[include:table1_ZEB2.md]]

          +[[include:tables/table1_ZEB2.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZFAT.md
			
          @@ -11,7 +11,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZFAT.md]]

          +[[include:tables/table1_ZFAT.md]]

           ## Warnings

				ZFP36L1.md
			
          @@ -13,7 +13,7 @@ ZFP36L1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ash

           ## Relevance tier by entity

          -[[include:table1_ZFP36L1.md]]

          +[[include:tables/table1_ZFP36L1.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZFX.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZFX.md]]

          +[[include:tables/table1_ZFX.md]]

           ## Warnings

				ZIC4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZIC4.md]]

          +[[include:tables/table1_ZIC4.md]]

				ZMYM4.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZMYM4.md]]

          +[[include:tables/table1_ZMYM4.md]]

				ZNF117.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF117.md]]

          +[[include:tables/table1_ZNF117.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF217.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF217.md]]

          +[[include:tables/table1_ZNF217.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF229.md
			
          @@ -15,7 +15,7 @@ Due to [minimal support](ZNF229#representative-mutation) in the original primary

           ## Relevance tier by entity

          -[[include:table1_ZNF229.md]]

          +[[include:tables/table1_ZNF229.md]]

           ## Warnings

				ZNF292.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF292.md]]

          +[[include:tables/table1_ZNF292.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF296.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF296]]

          +[[include:tables/table1_ZNF296]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF354A.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF354A.md]]

          +[[include:tables/table1_ZNF354A.md]]

				ZNF366.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF366.md]]

          +[[include:tables/table1_ZNF366.md]]

				ZNF385B.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF385B.md]]

          +[[include:tables/table1_ZNF385B.md]]

				ZNF423.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF423.md]]

          +[[include:tables/table1_ZNF423.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF439.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF439.md]]

          +[[include:tables/table1_ZNF439.md]]

				ZNF474.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF474.md]]

          +[[include:tables/table1_ZNF474.md]]

				ZNF521.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF521.md]]

          +[[include:tables/table1_ZNF521.md]]

				ZNF608.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF608.md]]

          +[[include:tables/table1_ZNF608.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF700.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF700.md]]

          +[[include:tables/table1_ZNF700.md]]

				ZNF790.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF790.md]]

          +[[include:tables/table1_ZNF790.md]]

				ZNF814.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF814.md]]

          +[[include:tables/table1_ZNF814.md]]

				ZNF85.md
			
          @@ -10,7 +10,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF85.md]]

          +[[include:tables/table1_ZNF85.md]]

           ## Mutation incidence in large patient cohorts (GAMBL reanalysis)

				ZNF91.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZNF91.md]]

          +[[include:tables/table1_ZNF91.md]]

           [[include:tables/mermaid_ZNF91.md]]

				ZP1.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZP1.md]]

          +[[include:tables/table1_ZP1.md]]

           [[include:tables/mermaid_ZP1.md]]

				ZWILCH.md
			
          @@ -13,7 +13,7 @@ nocite: |

           ## Relevance tier by entity

          -[[include:table1_ZWILCH.md]]

          +[[include:tables/table1_ZWILCH.md]]

           [[include:tables/mermaid_ZWILCH.md]]

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_ABCA3.md]]
	13	+[[include:tables/table1_ABCA3.md]]
14	14
15	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16	16

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_ABCB1.md]]
	13	+[[include:tables/table1_ABCB1.md]]
14	14
15	15	[[include:tables/mermaid_ABCB1.md]]
16	16

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ABCC9]]
	16	+[[include:tables/table1_ABCC9]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -15,7 +15,7 @@ Mutations were first described in DLBCL in 2013 by Morin et al.[@morinMutational
15	15
16	16	## Relevance tier by entity
17	17
18		-[[include:table1_ABI3BP]]
	18	+[[include:tables/table1_ABI3BP]]
19	19
20	20	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21	21

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_ABL2.md]]
	13	+[[include:tables/table1_ABL2.md]]
14	14
15	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16	16

...	...	@@ -13,7 +13,7 @@ Due to [minimal support](ACAD9#representative-mutation) in the original primary
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ACAD9]]
	16	+[[include:tables/table1_ACAD9]]
17	17
18	18
19	19	## Warnings

...	...	@@ -15,7 +15,7 @@ Due to [minimal support](ACE#representative-mutation) in the original primary da
15	15
16	16	## Relevance tier by entity
17	17
18		-[[include:table1_ACE]]
	18	+[[include:tables/table1_ACE]]
19	19
20	20	## Warnings
21	21

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ACSM3]]
	16	+[[include:tables/table1_ACSM3]]
17	17
18	18
19	19	[[include:tables/mermaid_ACSM3.md]]

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ACSS2]]
	16	+[[include:tables/table1_ACSS2]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ACSS3.md]]
	16	+[[include:tables/table1_ACSS3.md]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -16,7 +16,7 @@ ACTB is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
16	16
17	17	## Relevance tier by entity
18	18
19		-[[include:table1_ACTB]]
	19	+[[include:tables/table1_ACTB]]
20	20
21	21
22	22	## Mutation incidence in large patient cohorts (GAMBL reanalysis)

...	...	@@ -19,7 +19,7 @@ The function of mutations in ACTB and ACTG1 have not yet been determined.[@witje
19	19
20	20	## Relevance tier by entity
21	21
22		-[[include:table1_ACTG1]]
	22	+[[include:tables/table1_ACTG1]]
23	23
24	24	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25	25

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ACTN1]]
	16	+[[include:tables/table1_ACTN1]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ADAM2]]
	16	+[[include:tables/table1_ADAM2]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -15,7 +15,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
15	15	## Relevance tier by entity
16	16
17	17
18		-[[include:table1_ADAMTS1]]
	18	+[[include:tables/table1_ADAMTS1]]
19	19
20	20	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21	21

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ADAMTS15]]
	16	+[[include:tables/table1_ADAMTS15]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_ADAMTS5]]
	13	+[[include:tables/table1_ADAMTS5]]
14	14
15	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16	16

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ADAMTSL3]]
	16	+[[include:tables/table1_ADAMTSL3]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ADD2]]
	16	+[[include:tables/table1_ADD2]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ADH7]]
	16	+[[include:tables/table1_ADH7]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_ADNP]]
	13	+[[include:tables/table1_ADNP]]
14	14
15	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16	16

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_AFAP1L2]]
	16	+[[include:tables/table1_AFAP1L2]]
17	17
18	18
19	19	## Mutation incidence in large patient cohorts (GAMBL reanalysis)

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_AGA]]
	16	+[[include:tables/table1_AGA]]
17	17
18	18
19	19

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_AGO4]]
	13	+[[include:tables/table1_AGO4]]
14	14
15	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16	16

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_AHR]]
	16	+[[include:tables/table1_AHR]]
17	17
18	18
19	19	[[include:tables/mermaid_AHR.md]]

...	...	@@ -10,7 +10,7 @@ nocite: \|
10	10
11	11	## Relevance tier by entity
12	12
13		-[[include:table1_AICDA]]
	13	+[[include:tables/table1_AICDA]]
14	14
15	15	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
16	16

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_AKAP6]]
	16	+[[include:tables/table1_AKAP6]]
17	17
18	18
19	19	## Mutation incidence in large patient cohorts (GAMBL reanalysis)

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_AKAP8]]
	16	+[[include:tables/table1_AKAP8]]
17	17
18	18
19	19

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_AKAP9]]
	16	+[[include:tables/table1_AKAP9]]
17	17
18	18
19	19	[[include:tables/mermaid_AKAP9.md]]

...	...	@@ -13,7 +13,7 @@ nocite: \|
13	13
14	14	## Relevance tier by entity
15	15
16		-[[include:table1_ALAS1]]
	16	+[[include:tables/table1_ALAS1]]
17	17
18	18	## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19	19